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ABSTRACT 
Michael Aaron Collier: Formulation, and Characterization of Carrier Vehicles for Infectious 
Disease Treatment and Modulation of the Innate Immune System  
(Under the direction of Kristy M. Ainslie) 
 
Infectious diseases have become a significant problem worldwide because drug-resistant 
pathogen strains can limit treatment efficacy. To complicate treatment further, an inefficient 
number of pathogen-mediated therapeutics have made their way through the clinical pipeline, 
which equates to fewer treatment options. Fewer treatment options and more robust pathogens 
have generated a need for therapies with minimal resistant-based complications. By modulating 
pathogen-mediated therapeutic pharmacokinetic profiles, generating robust vaccines, and 
developing therapies which directly strengthen innate immune responses to clear infections, 
resistant-based complications may be reduced, aiding an extremely complicated worldwide 
epidemic. Here, drug delivery strategies including electrohydrodynamic spraying and spinning, 
emulsion based solvent displacement, and thin-film hydration are employed to combat resistance-
based complications and further the optimization of particulate based carriers for vaccines, host-
mediated therapies, and long-acting injectable formulations.      
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Chapter 1: Introduction 
1.1 Scope of Infectious Diseases and Treatment Complications 
The World Health Organization (WHO) defines an infectious disease (ID) as an infection 
caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi. Some of the 
deadliest IDs are caused by human immunodeficiency virus (HIV) (a virus), Plasmodium sp. (a 
parasite), and Mycobacterium tuberculosis (a bacteria). The IDs caused by these three pathogens 
alone accounted for roughly 4.1 million deaths worldwide in 2015. While these pathogens are 
perhaps the most well-known, other dangerous pathogens exist that are also serious health risks, 
as the total number of deaths caused from ID rank 2nd worldwide behind cardiac disease and ahead 
of cancer, as noted by the WHO. For a large number of IDs, the total occurrence has lessened in 
recent years due to better early detection methods, increased treatment options, and growing 
knowledge worldwide of the dangers associated with these infections. Unfortunately, even with 
the improvements made, mortality from many of these diseases has remained relatively constant.  
Typically, once diagnosed with an infection, treatment is prescribed that directly effects 
the pathogen of interest’s life cycle such as targeting protein biosynthesis, disrupting membrane 
structure, or modulating DNA/RNA synthesis inhibition within the pathogen (1). Pathogen-
mediated treatment can be successful when prescribed appropriately, and when the patient 
complies with the prescribed treatment regimen. Unfortunately, since the discovery and 
implementation of antibiotics, antivirals, antifungals, and antiparasitic therapeutics, treatment 
complications have arisen due to pathogen resistance to the pathogen-mediated therapeutics (2). 
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Perhaps the most common or well-known resistant bacteria, methicillin-resistant Staphylococcus 
aureus (MRSA) has become endemic in hospitals worldwide because of its ability to resist 
multiple families of antibiotics (3).   
Pathogen resistance to pathogen-mediated therapies can primarily occur in two different 
ways: intrinsic or acquired mechanisms. Intrinsic resistance mechanisms occur when bacterial 
genes mutate when exposed to a drug, resulting in reduced drug efficacy (4). Acquired resistance 
mechanisms occur when microbes gain DNA, often horizontally from the infected host or from 
other bacteria in the form of plasmids, and are integrated into the bacterial genome (4). Acquired 
or intrinsic resistant mechanisms illustrate that pathogenic genomes are sensitive and dynamic. 
Pathogens contain less robust genetic repair mechanisms and replicate much faster than humans. 
Thus, they can alter their genetic makeup quickly to respond to their environment. When a 
pathogen is exposed to a pathogen-mediated therapeutic at sub-optimal concentrations, it has the 
potential to rapidly and efficiently mutate to develop some tolerance towards the therapy. This 
pathogen and its offspring will then be less sensitive to the specific therapy, and will stand a better 
chance of surviving the formerly “therapeutic” dose. A common example of intrinsic resistance 
with MRSA is the generation of bacterial efflux pumps. These pumps actively remove antibiotics 
from intracellular environments and are associated with multi-drug resistance (MDR), which is 
one reason why MRSA treatment has become so difficult (5).  
MDR may occur when druggable targets in the pathogen have been repeatedly exposed to 
attack from multiple families of pathogen-mediated compounds. A druggable target is defined as 
a unique structure with which drugs are designed to interact with high affinity, such as the lipid 
membrane of gram-positive bacteria for antibiotics in the Type-A lantibiotic family (6). The ability 
for pathogens to mutate druggable targets like cell receptors, enzymes, and ion channels has 
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limited the effect of drugs that directly act on microbes (7). While pathogen-mediated therapies 
can be successful, their shelf life as effective therapeutics are significantly shorter than initially 
thought. The pathogen resistance complications, compounded with the fact that fewer pathogen-
mediated therapies have been approved for use in recent years (8) limits therapeutic options for 
the foreseeable future. Many scientists have claimed that we have reached the end of the antibiotic 
era, and in order to treat infections, other strategies must be used to combat ID.  
1.2 Use of Host-mediated Therapies to Treat Disease 
One potential strategy to combat IDs and pathogen-resistance, is by switching the target 
organism of the chosen therapeutic. A host-mediated therapeutic is defined as a compound which 
stimulates the hosts innate immune system to combat pathogens in a non-specific manner and 
contains very little risk of cultivating resistant pathogen strains. There is minimal risk of resistance 
because the innate immune system has numerous pathways in which it attacks pathogens, rather 
than focusing on a single druggable target. Compounds described as pathogen associated 
molecular patterns (PAMPs) can cause signaling cascades resulting in pro-inflammatory cytokine 
production for robust innate immune responses. This is facilitated through PAMPs binding to 
pattern recognition receptors (PRRs) within host-cells such as toll-like receptors (TLRs), 
nucleotide binding oligomerization domain-like receptors (NLRs), c-type lectin receptors (CLRs), 
RIG-I-like helicases (RLH), and many others. While PRRs are present within most cell types, it is 
widely recognized that antigen presenting cells (APCs) such as dendritic cells and macrophages 
have the largest quantity of PRRs present within them (9).  
Elicitation of a strong innate immune response is typically characterized by enhanced 
microbicidal mechanisms and recruitment of monocytes, neutrophils, and natural killer cells to the 
site of infection to aid in the removal of pathogens (10). Certain pathogens have the ability to 
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dampen innate immune signaling upon infection, which reduces the ability of the immune system 
to clear the pathogen on its own (11). By using host-mediated therapeutics, the ability of the 
pathogen to dampen immune responses can be counteracted and the pathogen can be cleared 
without the use of host-mediated therapies.  
1.3 Use of Vaccines to Prevent Disease 
Another potential strategy for combating IDs and pathogen-resistance is by generating 
robust adaptive immune responses towards pathogens through prophylactic administration of a 
vaccine. Vaccines are widely regarded as the single greatest medical innovation of the modern era 
for their ability to protect entire populations from outbreaks, and to eradicate IDs. There are many 
types of vaccines that have been Food and Drug Administration (FDA) approved within the United 
States; however, the safest form of vaccines currently used is considered to be the subunit vaccine 
(12). A subunit vaccine is comprised of a component of a pathogen, which minimizes the number 
of danger signals present within the formulation. This portion of the pathogen is referred to as an 
antigen, and antigens are ultimately what will be recognized by the immune system on the intact 
pathogen if the vaccinated individual is ever infected. When APCs successfully process the 
antigen, they present the immunodominant epitope of the antigen on the major histocompatibility 
complex (MHC), which allows for Tcell recognition of the epitope (13). While the use of a subunit 
vaccine is often safe, it is not always efficacious by itself because antigens typically do not elicit 
a strong innate immune response, which is required for high levels of epitope presentation on 
MHCs. In order to strengthen subunit vaccines, an adjuvant is often administered alongside the 
antigen, which creates a robust innate immune response, allowing for a strong adaptive response.  
Adjuvants can skew the immune system towards a Th1 (cytotoxic Tcell mediated) or Th2 
(antibody mediated) response. Of approved adjuvanted vaccines, a majority contain aluminum 
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salts (Alum), AS03, or MF59 which are all potent Th2 skewing immune activators (14-16). These 
vaccines are quite effective when the pathogen of interest is cleared in an antibody dependent 
manner; however, if a cytotoxic Tcell response is required, the vaccine will not generate a 
successful adaptive immune response. Recently, the Cervarix vaccine was FDA approved and 
contains the AS04 adjuvant system. AS04 contains Alum and monophosphoryl lipid A (MPL). 
MPL is a PAMP that binds to TLR-4. This combined adjuvant system incorporates Th2 skewing 
Alum and Th1 skewing MPL to create a more well-rounded adaptive immune response (14, 17). 
While AS04 represents a progression within the adjuvant field to generate Th1 skewing, there is a 
clear need for more effective adjuvants to create stronger vaccines in the future.  
1.4 Drug Delivery for Treatment of Infectious Diseases  
While both host-mediated therapeutics and vaccines offer effective alternatives to treating 
and preventing IDs, there are inherent drawbacks to both strategies. A major drawback of host-
mediated drugs, compared to pathogen-directed therapies, are that they typically have enhanced 
toxicity toward host cells. Additionally, delivery through oral administration, solubility of host-
mediated therapies, and delivery to APCs remain major hurdles. Vaccines also suffer from poor 
delivery to APCs, as antigens must reach dendritic cells or macrophages to be presented to Tcells 
for adaptive responses. Furthermore, IDs are often observed within tropical regions of the world 
and cold-chain storage must be maintained for many therapeutics to retain efficacy, which can 
drastically increase the cost of treatment (18). Lastly, vaccine adjuvants can be PAMPs, which can 
have enhanced toxicity towards host cells. The benefits for each strategy are clear; however, 
overcoming the barriers of these strategies are imperative for future clinical success.  
To overcome these barriers, as well as many others, drug delivery vehicles (e.g. micelles, 
liposomes, polymeric particles) can be employed. Cancer therapy has seen a vast increase in drug 
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delivery research because improved delivery reduces unwanted side effects such as cardiotoxicity 
and peripheral neurotoxicity (19). Besides the potential to reduce drug toxicity, drug 
hydrophobicity is a primary reason to encapsulate in a delivery vehicle. Some efficacious host-
mediated therapeutics available for topical delivery (e.g. imiquimod) (20) are unable to be 
delivered systemically at therapeutic concentrations because they precipitate out of an aqueous 
solution (they are too hydrophobic). Additionally, enhanced delivery to APCs with acid sensitive 
materials allows for more efficient immune system activation, and can lead to better adaptive 
responses (21, 22). Furthermore, drug encapsulation into a vehicle has been repeatedly shown to 
significantly increase the area under the curve (AUC) for a compound (23) through extended 
circulation times and protection from degradation and clearance.   
1.4.1. Liposomes 
Liposomes are small lipid-based vesicles that can encapsulate both hydrophobic and 
hydrophilic drugs. Typically, hydrophilic drugs are encapsulated within the aqueous core and 
hydrophobic drugs are encapsulated within the lipid tails of the bilayer. When the liposome 
becomes unstable and the bilayer is disrupted, drugs can be released quite readily. Liposomes can 
have varying physical characteristics according to the individual lipid components used to create 
the liposome, such as stealth through poly-ethylene glycol (PEG) coating (24), APC targeting with 
mannose incorporation (25), or acid sensitivity with calcium phosphate cores (26). Typically, 
unilamellar (a single bilayer) liposomal formulations have a hydrodynamic diameter of roughly 
100 nm; however, there is minimal flexibility with this size due to thermodynamic interplay within 
the bilayer. Multilameller (multiple bilayers) liposomal formulations can have a hydrodynamic 
diameter of roughly 1-3 µm; however, their physical properties are less uniform due to non-
homogenous bilayer quantities.  
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Liposomes are widely regarded as safe due to biologically relevant byproducts generated 
when the carrier degrades. The FDA-approved anti-infective liposome Ambiosome® contains the 
hydrophobic drug amphotericin B, and is used for parasitic and fungal infections with success. 
Additionally, there are the FDA-approved liposomal vaccines Inflexal and Epaxal that have shown 
efficacy since reaching the clinic (27, 28). Furthermore, the Walter Reed Army Institute of 
Research has a liposomal based HIV vaccine within clinical trials that has shown promising results 
(29).  
1.4.2. Polymeric Particles 
In the last 25 years, polymeric particles have become a popular and dynamic drug 
delivery strategy. With this platform, a drug is typically encapsulated in a polymer matrix, 
wherein the drug is uniformly dispersed throughout the polymer and released by diffusion and/or 
polymer degradation. Polymer based particles are widely regarded to be more stable 
formulations than liposomes, and formulations of polymeric particles can yield hydrodynamic 
diameters of a large range, typically from 10’s of nm to 100’s of µm, depending on the 
formulation technique (30). While any number of polymers can be used for drug delivery, poly 
lactic-co-glycolic acid (PLGA) is by far the most common due to its low cost, low toxicity, 
biocompatible degradation byproducts, and degradation kinetics (31). In fact, more than 15 
formulations containing PLGA have been FDA-approved for use (32).  
One of the hallmarks of PLGA is the long degradation kinetics allowing for slow release 
of small molecule drugs. This extended release allows for modulation of a therapeutics’ 
pharmacokinetic (PK) parameters. Extended release PLGA formulations have been used quite 
extensively for treatment of schizophrenia to combat poor adherence to oral formulations (33). By 
extending the release time of the therapeutic, there are fewer administrations needed, allowing for 
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better adherence by the patient as well as administration without patient compliance. Better 
adherence can equate to spending significantly less time with sub-therapeutic concentrations of 
drug, which, when applied to IDs would minimize the risk for emergence of drug resistance.     
While PLGA has numerous benefits for long term release of therapeutics, acute release 
from PLGA is more difficult as degradation half-lives can range from months to years, with 
minimal pH sensitivity (34). Additionally, the acidity of PLGA degradation byproducts (lactic 
and glycolic acid) can be harmful to cargo encapsulated within the particles (35). To more 
adequately deliver vaccines and host-mediated therapeutics in polymeric vehicles, it is clear that 
alternate polymers must be used.   
Acetalated dextran (Ace-DEX) is a newly developed biodegradable polymer which is 
synthesized from dextran, a hydrophilic polysaccharide. As the acetalation reaction occurs, acyclic 
acetals form rapidly, displacing the hydroxyl groups on dextrans glucose rings. Acyclic acetals are 
acid sensitive and weakly resist hydrolytic cleavage. As the reaction proceeds, cyclic acetals form, 
which are also acid sensitive, but strongly resist hydrolytic cleavage (36). By changing the reaction 
times, and in turn, the ratio of cyclic to acyclic acetals, the degradation kinetics of Ace-DEX can 
be finely tuned. The resulting product is an acid sensitive, hydrophobic polymer with biologically 
relevant degradation products of acetone, ethanol, and dextran. In the phagosomal compartments 
of APCs, Ace-DEX can have degradation half-lives of minutes to hours allowing for quick 
intracellular delivery of therapeutics whereas degradation half-lives in pH neutral environments 
can range from days to weeks (37, 38). PLGA has much longer degradation half-lives within 
phagosomal compartments, and drug release has been noted to take place over 13 days post 
phagocytosis (39). Kupffer cells and splenic macrophages have lifetimes of less than a week and 
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thus delivery of therapeutic in which not all of the drug is utilized would be less than ideal (40, 
41). 
Another benefit of Ace-DEX is that it can overcome the need for cold-chain storage that 
many therapeutics require. It has been demonstrated that an enzyme encapsulated within Ace-
DEX MPs, illustrated stable activity across a broad range of temperatures inside and outside the 
cold chain, indicating enhanced cargo stability (42) which is needed in the desert and tropical 
regions where many pathogens are endemic (43). Polyesters such as PLGA and polycaprolactone 
(PCL) do not retain their stability outside of the cold chain, and thus, have additional treatment 
costs (44). 
1.5 Objective and Research Contribution 
Treatment of IDs and the pathogens that cause them is becoming more difficult due to 
resistance based complications and rapidly mutating pathogen strains. Using drug delivery 
strategies to deliver host-mediated therapeutics, vaccines, and modulate the PK of effective 
therapies have the potential to reduce toxic side effects of the parent molecules, enhance delivery 
to APCs where the molecules can be most efficacious and reduce adherence related resistance 
complications. The work detailed within this thesis addresses some of the complications and 
successes of formulating both polymeric and liposomal particles to combat ID with host-mediated 
therapeutics, vaccines, and long-acting injectables. While the experiments performed and the 
knowledge gained from this work is mostly academic, the information gathered for future 
technologies could lead to more substantial discoveries within the field of treating IDs.  
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Chapter 2: Formulation of AR-12 Acetalated Dextran Microparticles to Modulate 
Macrophage Activity Against Intracellular Pathogens  
2.1 Introduction  
Intracellular pathogens are some of the most difficult infections to treat because the host 
cell provides an additional barrier for the therapeutic to cross. These pathogens can be 
characterized as obligate when they multiply strictly within a host cell, or facultative when the 
organism grows either intracellularly or extracellularly (45). Due to the complex location of these 
intracellular infections and lapses in patient compliance, resistance to pathogen-mediated 
therapeutics has become common, significantly decreasing treatment efficacy.  
A variety of host cells can be infected by microbes; however, a majority of infections exist 
in antigen presenting cells (APCs) due to their high phagocytic activity. Intracellular pathogens 
have the ability to evade and suppress innate immune responses within APCs that assist in 
clearance of infections such as generating vacuoles to evade the phagocyte oxidase complex within 
macrophages, blocking lysosomal fusion, and inhibiting macrophage nitric oxide species 
production (46, 47). Host-mediated therapeutics offer a means to circumvent resistance 
mechanisms by targeting the host cell rather than the pathogen (48). Because these pathogens are 
capable of both inhibiting or dampening the innate immune system and developing resistance to 
pathogen-mediated therapeutics, it becomes imperative to develop host-mediated therapies that 
can assist in effective clearance without the associated resistance complications. 
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One novel host-mediated compound with the potential to clear intracellular pathogens is 
AR-12 (formerly known as OSU-03012), an IND-approved derivative of Celecoxib that lacks 
Cyclooxygenase-2 inhibitor activity. AR-12 has been reported to enhance host-mediated 
eradication of numerous intracellular pathogens through up-regulation of autophagy via the Akt 
kinase pathway (49-53). The autophagy process first forms a double membrane autophagosome 
that surrounds cellular components or pathogens, and then fuses with the lysosome or late 
endosome for destruction, allowing cells to recycle cytoplasmic constituents and destroy 
intracellular pathogens (54). In vivo, soluble AR-12 administration resulted in a reduction of 
Salmonella enterica serovar Typhimurium and Francisella tularensis bacterial loads in multiple 
organs, along with a significant increase in survival time of infected mice; however, the soluble 
AR-12 treated mice ultimately succumbed to infection (49, 55). AR-12 is noted as being fairly 
hydrophobic with a solubility of < 1mg/mL in water, and studies have shown that cellular 
internalization of soluble AR-12 is an inefficient process (56). Additionally, soluble AR-12 is 
fairly cytotoxic, causing greater than 50% cell death at concentrations of 5µM, which limits the 
therapeutic range that can be explored. While soluble AR-12 showed promising initial results, it 
is clear that the hydrophobicity and toxicity concerns severely limit its use both in vitro and in 
vivo. 
One way to overcome the limitations of soluble AR-12 is through formulation of a drug 
delivery vehicle. Drug delivery vehicles, such as liposomes and polymeric microparticles (MPs), 
are known to mitigate drug hydrophobicity, reduce toxicity, and increase therapeutics’ area under 
the curve (48). Using an emulsion-based solvent evaporation method and the acid-sensitive 
biopolymer acetalated dextran (Ace-DEX), AR-12 microparticles (AR-12/MPs) were formulated 
to passively target macrophages. Ace-DEX was chosen as the delivery vehicle because it degrades 
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rapidly within the low pH environment of APC lysosomes (36), whereas other biodegradable 
polymers such as poly lactic-co-glycolic acid (PLGA) have minimal pH sensitivity (34). 
Additionally, Ace-DEX is known to have cryoprotectant capabilities and can protect encapsulated 
cargo outside of the cold-chain, potentially reducing the cost of treatment (42).  
AR-12/MPs showed a large reduction in cytotoxicity on murine bone marrow derived 
macrophages and human monocyte derived macrophages when compared to soluble AR-12 (56). 
Additionally, AR-12/MPs demonstrated efficacy in vitro when incubated with infected 
macrophages, but not when incubated with the pathogen alone, indicating the requirement for host-
mediated action (57). In vivo, AR-12/MPs were more effective at clearing pathogens than soluble 
AR-12 was, indicating dose sparing, which is one of the most beneficial and desirable traits of new 
therapies due to a reduction in costs and toxic side effects (58). Furthermore, there was enhanced 
clearance of pathogens when AR-12/MPs were administered with other pathogen-mediated 
therapeutics, revealing potential synergistic combinations (56, 57).  
While all of these findings showed great promise for AR-12/MPs, some of the 
shortcomings of the formulation needed to be addressed. This chapter investigated the formulation 
of AR-12/MPs, particle trafficking within mice based on different administration routes, lysosomal 
escape once AR-12/MPs are internalized in phagocytic cells, and effective sterilization of AR-
12/MPs for clinical applications.   
2.2 Materials and Methods 
2.2.1. Chemicals 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise 
noted. AR-12 was from Arno Therapeutics (Flemington, NJ, USA). Water was purified using a 
Millipore (Billerica, MA, USA) Milli-Q Integral water purification system. Fluorescence and 
13 
 
absorbance measurements were obtained with a Molecular Devices (Sunnyvale, CA, USA) Spectra 
Max M2 plate reader. 
2.2.2. Production of Acetalated Dextran and Texas-red Actetalated Dextran 
Ace-DEX polymer was synthesized using 71 kDa dextran from Leuconostoc 
mesenteroides. To synthesize 71kDa Ace-DEX, lyophilized 71kDa dextran and pyridinium p-
toluenesulfonate (0.0617 mmol) were dissolved in anhydrous dimethyl sulfoxide (DMSO). 
Dissolved dextran was reacted with Matrix (Columbia, SC, USA) 2-ethoxy-propene under 
nitrogen gas at room temperature for 30 minutes. After 30 minutes, reactions were quenched with 
an excess of trimethylamine (TEA). The reaction volumes were then precipitated in basic water 
(.04/99.96% v/v TEA and water, respectively), and centrifuged using a Thermo Scientific Sorvall 
Legend XTR centrifuge (Waltham, MA, USA) to remove any remaining water-soluble 
polysaccharides (i.e., un-acetalated dextran and/or lowly acetalated dextran). The resulting pellet 
was then frozen and lyophilized overnight. The following day, the product was dissolved in ethanol 
and centrifuged to further purify the polymer. The supernatant was precipitated in basic water, 
centrifuged again, frozen and lyophilized to yield 71 kDa Ace-DEX polymer. The extent of cyclic 
acetal formation was determined using 1H nuclear magnetic resonance (NMR) spectroscopy. 
70 kDa Texas-red dextran was purchased from Thermo Fisher Scientific (Grand Island, 
NY, USA). Using a blend of normal dextran with Texas-red dextran, the acetalation process was 
performed as stated above.  
2.2.3. Production of AR-12, Coumarin-6, Indocyanide Green, or Texas-red Ace-DEX 
Particles  
To prevent endotoxin contamination, all dishes and glassware were soaked in 1.0M sodium 
hydroxide overnight, washed with isopropanol, and dried before use. Ace-DEX was combined 
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with AR-12, coumarin-6, or indocyanide green (ICG) at varying wt.% and dissolved in 
dichloromethane (DCM) or ethyl acetate (EA). To this solution, polyvinyl alcohol (87-89% 
hydrolyzed) (PVA) (3% wt/wt) in phosphate buffer saline (PBS, pH 7.4) was added and the 
mixture was sonicated on ice using a Misonix Ultrasonic Liquid Processor (Farmingdale, NY; 60 
W, duty cycle 50%). The emulsion was placed in 0.3% PVA in PBS and stirred for 3 hours to 
evaporate the organic solvent. To remove un-encapsulated drug, the solution was centrifuged and 
washed in basic water three times using a Thermo Scientific Sorvall Legend XTR centrifuge 
(Waltham, MA, USA). The particles were collected, frozen, and lyophilized. To create empty MPs, 
the same procedure was used without the addition of drugs. Prior to use, both loaded MPs and 
empty MPs were confirmed to have endotoxin levels below FDA guidelines (0.25 endotoxin units 
per milliliter) by a GenScript USA Inc. ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit 
(Piscataway, NJ, USA), performed according to the manufacturer’s instructions.  
Texas-red Ace-DEX microparticles (Tx-red/MPs) were produced using the same protocol 
as above, but with a blend of 10% Texas-red Ace-DEX and 90% normal Ace-DEX polymer. 
Rather than freezing and lyophilizing, Tx-red/MPs were suspended in media and used immediately 
following the wash steps.  
2.2.4. Size, Imaging and Encapsulation of AR-12/MPs 
Hydrodynamic diameter was determined by suspending particles at 0.1 mg/mL in basic 
water and using a Brookhaven (Holtsville, NY, USA) BI-200SM machine for dynamic light 
scattering (DLS) analysis. AR-12/MPs were imaged using a Hitachi S-4700 Cold Cathode Field 
Emission Scanning Electron Microscope (SEM) located at the University of North Carolina at 
Chapel Hill. MPs were suspended in basic water, placed on an SEM stub, and allowed to air-dry. 
SEM images were used to confirm size and polydispersity results obtained with the DLS, and to 
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ensure all un-encapsulated drug was removed during washing. Encapsulation efficiency (EE) was 
determined by preparing a 1mg/mL solution of AR-12/MPs in DMSO alongside a standard curve 
of un-encapsulated AR-12 dissolved in DMSO. The samples were read on a plate reader at λex 
280nm/λem 380nm, and the amount of AR-12 encapsulated within the MPs was calculated using 
the regression analysis of the un-encapsulated AR-12 standard curve.  
2.2.5. AR-12/MP Release Profile 
AR-12/MPs and empty MPs (n= 3) were suspended at a concentration of 0.5 mg/mL in 
either PBS (pH 7.4) to mimic physiological pH or sodium acetate (pH 5.0) to mimic the acidic pH 
of endosomes, lysosomes, and areas of inflammation. Once suspended, these particles were placed 
on a Thermo Fisher Scientific (Waltham, MA, USA) Multi-Blok Heater shaker hot plate at 37 °C. 
Before adding to the hotplate, 150 µL was removed from the neutral pH solution and centrifuged 
at 21,000 G for 10 minutes in a Thermo Fisher Scientific Legend Micro 21 Centrifuge benchtop 
centrifuge at 4 °C. The supernatant was removed and the particle pellet was frozen. At each time 
point, 150 µL was removed from each sample, centrifuged, decanted, and the pellet was frozen. 
Once all time points had been collected, the samples were placed under N2 to dry completely and 
then dissolved in methanol. Each sample was placed into a 96-well plate and read on a plate reader 
at λex 280nm/λem 380nm, and the percent of AR-12 retained within the MPs at each time point was 
calculated. 
2.2.6. Confocal Imaging of Coumarin-6 and Texas-red MPs  
RAW 264.7 macrophages purchased from ATCC (Manassas, VA, USA) were cultured 
using Corning (Tewksburry, MA, USA) DMEM media according to directions. Cells were seeded 
at 2x105 cells/mL in Thermo Fisher Scientific chambered coverglass wells overnight before use. 
For coumarin-6 Ace-DEX MPs (Coumarin-6/MPs), Thermo Fisher Scientific Lyso-tracker Red 
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(LTR) was added for 2 hours before imaging and washed off of cells with media three times. 
Coumarin-6/MPs suspended in media were added to the cells for 10 minutes before being washed 
with media to remove un-internalized particle fluorescence. Imaging was performed on a Zeiss 
LSM 710 confocal microscope located at the University of North Carolina at Chapel Hill.  
For Tx-red/MPs, cells were seeded as above and Thermo Fisher Scientific Lyso-tracker 
green (LTG) was added 2 hours before imaging and washed off of cells with media three times. 
Tx-red/MPs suspended in media were added to the cells for 10 minutes before being washed with 
media to remove un-internalized particle fluorescence. Imaging was performed on a Zeiss LSM 
710 confocal microscope located at the University of North Carolina at Chapel Hill.   
2.2.7. Maximum Tolerated Dose of AR-12/MPs  
A traditional 3+3 dose escalation was used to determine the maximum tolerated dose 
(MTD) of AR-12/MPs (59). 6-8 week old female Balb/c mice were weighed and assessed before 
administration to determine baseline weight and activity. Mice (n = 3) were administered AR-
12/MPs, soluble AR-12 dissolved in a soluble vehicle (Poly-eththylene glycol400:saline:ethanol, 
50:35:15), PBS, or soluble vehicle via intravenous, intranasal, or intraperitoneal routes. For 
intravenous administration, 100 µL was injected into the tail vein. For intranasal administration, 
mice were anesthetized via isoflurane inhalation and 10 µL was pipetted into each nostril (for a 
total of 20 µL) and were held until they regained consciousness. For intraperitoneal 
administrations, 100 µL was injected into the intraperitoneal space. Following administration, 
mice were weighed and monitored at regular time intervals to ensure their health was not at risk. 
If a mouse lost more than 15% of its pre-administration body weight it was determined that the 
dose was not tolerated, and that mouse was euthanized immediately. If all three mice survived the 
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dose of AR-12 that was administered, the dose was increased until the does was not tolerated to 
determine the MTD.      
2.2.8. Trafficking of Indocyanine Green Microparticles (ICG/MPs) in Vivo 
ICG/MPs were administered via the same routes as in the MTD study. Each administration 
route received 0.5 mg/kg of encapsulated ICG. At pre-determined time points, mice (n=4) were 
euthanized and organs of interest were harvested. Following extraction, organs were aligned and 
imaged using an In Vivo Imaging System (IVIS) kinetic with appropriate ICG settings.  
2.2.9. Sterilization of AR-12/MPs 
Formulated AR-12/MPs were sterilized by either gamma irradiation or ethylene oxide 
treatment. For gamma irradiation, particles were placed on dry ice and subjected to gamma-
irradiation for a total dose of 8.5 kGy using a Shepherd & Associates (San Fernando, CA, USA) 
Model Mark I-68; J.L collimator (Model 335) with a 137Cesium γ-ray source at a dose of 2.2 
Gy/min. We would like to acknowledge Anderson Products (Haw River, NC, USA) for providing 
ethylene oxide sterilization of AR-12/MPs.  
2.2.10 Degradation and Release of Sterilized AR-12/MPs  
To determine if particle sterilization affected the particle degradation rate or release profile, 
degradation and release studies were performed for sterilized and non-sterilized AR-12/MPs and 
Blank Ace-DEX MPs. Release studies were performed as described in 2.2.5. For degradation, 
particles were resuspended at a concentration of 1.5 mg/mL in either PBS (pH = 7.4) or 0.3 M 
sodium acetate buffer (pH 5.0). Samples were agitated on a shaker plate (150 rpm) at 37 °C. At 
predetermined time points, the solution was vortexed, and its absorbance at 600 nm was read using 
a plate reader. The degradation profile of MPs was determined by comparing their absorbance 
levels at different time points to the recorded absorbance at 0 hours. The percent degradation of 
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each sample is equal to the difference between its absorbance reading at the specified time point 
and that at 0 hours, divided by the absorbance reading at 0 hours. 
2.2.11. Efficacy of Sterilized AR-12/MPs  
To test efficacy of sterilized AR-12/MPs, they were applied to Salmonella enterica Typhi 
(S. Typhi) infected hMDMs. Overnight cultures of S. Typhi were prepared for infection of hMDMs 
by sub-culture (1:50) in Difco (Detroit, MI, USA) fresh Luria-Bertani (LB) broth and incubated 
for 4 hours at 37°C. Bacteria were then collected by centrifugation at 3,000g for 10 minutes and 
suspended in PBS to an optical density of 0.6 at 600nm, which was equivalent to 5×108 CFUmL−1. 
hMDMs were infected with S. Typhi at a multiplicity of infection (MOI) of 20:1 in the presence 
of 2% autologous serum in RPMI 1640 (Gibco-Life Technologies). Two hours after infection, 
extracellular bacteria were removed by adding gentamicin (100µg/mL) to the culture medium for 
1hour, followed by thoroughly washing the cell layer three times with pre-warmed RPMI 1640. 
The infected hMDMs were then treated with 5 µM of sterilized or non-sterilized AR-12/MPs and 
respective Blank MPs in fresh culture medium containing 2% autologous serum. Gentamicin was 
also added at 10µg/mL to eliminate potential re-infection by extracellular bacteria. At 22 hours 
post-administration, the infected cells were lysed with Calbiochem (San Diego, CA, USA) 0.1% 
Triton X-100 in PBS for 15 minutes. The cell lysates were then serially diluted in PBS and spread 
on LB agar plates. The surviving intracellular bacteria were determined by enumerating CFU after 
24 hour incubation at 37°C. 
2.3 Results 
2.3.1. Size, Imaging and Encapsulation Efficiency of AR-12/MPs 
AR-12/MPs were created by emulsion chemistry via sonication using either DCM or EA 
as the organic solvent. Regardless of the solvent, the particles appeared to have similar 
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morphologies and size ranges under SEM according to Figure 2.1. As measured by DLS, the size 
of the particles was determined to be 255 ± 45 nm for DCM particles and 260 ± 37 nm for EA 
particles. The EE was 31.50% for DCM particles and 80.25% for EA particles for 2% by wt. initial 
loading (Table 2.1). Increasing the loading of AR-12 from 2% by wt. up to 20% by wt. did not 
reduce the EE of EA particles (Table 2.2).   
2.3.2. AR-12/MPs Release Kinetics using Different Solvents 
The ability of AR-12/MPs to retain AR-12 in neutral and acidic environments was 
analyzed. In a pH 5.0 environment, AR-12 was released quickly from MPs with close to 100% 
release from both formulations shortly after 24 hours as seen in Figure 2.2 A. AR-12/MPs 
formulated using DCM released AR-12 from MPs more quickly than those formulated with EA at 
pH 7.4. After one week in pH 7.4 conditions, roughly 60% of AR-12 was released from the MPs 
formulated with DCM and approximately 15% of AR-12 was released from the MPs formulated 
with EA as seen in Figure 2.2 B.  
2.3.3. Confocal Imaging of Coumarin-6/MPs and Tx-red/MPs 
Coumarin-6/MPs were incubated with RAW macrophages for 10 minutes, washed, and 
then imaged using confocal microscopy. Following a 10 minute incubation, coumarin-6 dye was 
no longer associated with only the lysosome. In fact, the coumarin-6 was diffuse throughout the 
cytoplasm, showing lysosomal escape of the particle cargo (Figure 2.3 A). 
Tx-red/MPs were incubated with RAW macrophages and washed similarly to the 
Coumarin-6/MPs. The Tx-red/MPs show signs of beginning to degrade within lysosomes because 
Texas-red can be seen outside of the lysosomes (Figure 2.3 B). Neither the Texas-red, nor 
coumarin-6 dye were able to penetrate the nuclear membrane.  
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2.3.4. MTD of AR-12/MPs 
MTD experiments showed that for delivery to the intraperitoneal space, there was no 
benefit of encapsulating AR-12 as the maximum amount of AR-12/MPs that was possible to 
administer was 80 mg/kg and no higher doses were administered for soluble AR-12 (Table 2.3). 
However, for intranasal delivery, there was a clear advantage to using AR-12/MPs because there 
was an 8 fold increase in the MTD over the soluble form of the drug. The MTD of Blank MPs was 
found to be very similar to AR-12/MPs. For intravenous delivery, there was a marginal advantage 
to using AR-12/MPs over soluble AR-12, as the MTD was only increased by 1.5 fold. This was a 
drug-related phenomenon since the Blank MPs could be administered at much higher quantities 
than the AR-12/MPs.  
2.3.5. Trafficking of ICG/MPs in Vivo 
Trafficking of ICG/MPs was clearly dependent upon the route of administration. For 
intraperitoneal administration (Figure 2.4 A), the largest deposition was in the liver, kidneys, and 
spleen; however, after three hours there was a very large reduction of ICG in all organs. There was 
more accumulation in the inguinal lymph node than in the superficial cervical lymph node; 
however, there was drastic clearance from the lymph nodes compared to the rest of the organs.  
Intravenous administration (Figure 2.4 B) resulted in a large deposition of ICG in the liver, 
kidneys, and lungs. Like the intraperitoneal administration, there was a large reduction of ICG 
quantities in all organs following the six hour time point. There was initial accumulation within 
the lymph nodes with fairly rapid clearance, similar to the intraperitoneal administration.  
With intranasal administration (Figure 2.4 C), there was a large quantity of ICG in the 
lungs and the liver, but smaller quantities in all other organs. Over the study period, there was a 
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steady decline of ICG levels in all organs. There was accumulation in both the inguinal and 
superficial cervical lymph nodes with steady decline of ICG levels over time.   
2.3.6. Degradation and Release Kinetics of Sterilized AR-12/MPs 
In pH 5.0 environments, non-sterilized and sterilized particles have fairly similar release 
kinetics and degradation profiles as seen in Figure 2.5 A and C, respectively. In pH 7.4 
environments, there is very little change in degradation and release kinetics of sterilized particles 
and AR-12/MPs at early time points; however, following 400 hour time points, the sterilized 
particles degraded and released AR-12 much faster than the non-sterilized particles, as seen in 
Figures 2.5 B and D, respectively. Gamma irradiated particles had faster release and degradation 
rates than ethylene oxide and non-sterilized particles at pH 7.4.  
2.3.7. Efficacy of Sterilized AR-12/MPs against S. Typhi       
hMDMs were infected with S. Typhi and then treated with sterilized and non-sterilized 
AR-12/MPs (Figure 2.6). Following treatment, there was statistically significant bacterial 
knockdown with non-sterilized AR-12/MPs and both sets of sterilized AR-12/MPs. While ethylene 
oxide treated AR-12/MPs knock down bacterial loads less than non-sterilized and gamma 
irradiated AR-12/MPs, there was still significant knockdown with respect to blank particles.  
2.4 Discussion 
Intracellular infections remain a significant public health concern worldwide due to the 
emergence of drug resistant strains, increasing rates of co-infection, toxicity, and cost of current 
treatments (60). The development of new treatment approaches is vital and host-mediated therapies 
are one avenue for drug development. AR-12/MPs formulated with DCM had clear advantages as 
a host-mediated therapeutic vehicle, exhibiting controlled and sustained release for clearance of 
intracellular pathogens (55-57); however, it was hypothesized that modulation of the formulation 
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parameters and identifying the trafficking patterns of Ace-DEX MPs could make AR-12/MPs a 
more effective treatment.  
Alternative solvent systems were investigated to increase the EE of AR-12/MPs compared 
to the DCM formulation method. Switching the organic solvent from DCM to EA, allowed for a 
much higher EE (Table 2.1) most likely due to increased solubility of AR-12 in EA. In an emulsion 
process, the organic soluble components reside within the immiscible organic solvent when the 
bulk aqueous phase is added. If the drug and or polymer is not extremely soluble within the organic 
phase, it will diffuse readily into the bulk aqueous phase, lowering the EE (61). EE is important 
for clinically applicable formulations, as lower drug loading means higher excipient loads, which 
can make treatment difficult (62). 
The release kinetics of AR-12/MPs were also improved by changing the solvent system 
from DCM to EA; at physiological pH (7.4), there was significantly less AR-12 released from AR-
12/MPs, while release at pH 5.0 remained relatively unchanged over the same time frame (Figure 
2.2). This most likely stems from AR-12 being more homogenously distributed within the organic 
phase droplet in the emulsion. Additionally, if AR-12 is less soluble in DCM, it is possible that 
aggregates of AR-12 form within the organic phase droplet which can lead to faster overall release. 
Because the Ace-DEX polymer was unchanged in either solvent system, the degradation time was 
unchanged and thus, the differences are most likely predicated upon solvent-polymer-drug 
interactions.  
Once Ace-DEX particles are internalized within a phagocytic cell, the particles degrade 
rapidly, and it is theorized that acetal degradation allows for lysosomal rupture and release into the 
cytoplasm through increased lysosomal osmotic pressure (63). Using confocal microscopy, it was 
confirmed that the encapsulated hydrophobic dye coumarin-6 escaped the lysosome (as labeled by 
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LTR) and diffused throughout the cytoplasm within 10 minutes of particle incubation (Figure 2.3). 
PLGA particles also allow for lysosomal escape of cargo; however, there is no indication that 
lysosomal escape occurs before 30 minutes of incubation with human arterial smooth muscle cells 
(64). There is the potential that extracellular coumain-6 can diffuse through the cell membrane and 
have no interaction with the lysosome. To understand this, Tx-red/MPs were generated to view the 
polymers path through the lysosomal trafficking system. Tx-red/MPs travel through the lysosome 
(as labeled by LTG), and show signs of lysosomal escape, similar to the path of Coumarin-6/MPs. 
These data indicated that Ace-DEX particles released their cargo rapidly upon degradation in the 
low pH environment of the lysosome and delivered therapeutics into the cytosol, which is a key 
attribute for clinically relevant formulations (65). Other acid sensitive material such as poly (beta-
amino) esters allow for rapid cytosolic delivery; however, they are difficult to synthesize, lack the 
tunability inherent to Ace-DEX, and have shown cytosolic delivery at 4-6 hours post incubation 
(66). 
The sustained delivery and controlled release of AR-12 led to reduced cytotoxicity in vitro 
(56); however, the toxicity reduction in vivo has not previously been explored. In all previous 
work, AR-12/MPs of 2% initial wt. loading were used to deliver AR-12 (55-57), but to determine 
MTD, a higher drug-to-excipient ratio was used. AR-12 loading increased sustainably, up to 20% 
initial wt. loading without a significant decrease in the EE (Table 2.2). The 20% initial wt. AR-
12/MPs formulated with EA yielded a drug loading similar to that of Risperdal Consta, an FDA 
approved PLGA formulation; however, the EE achieved for AR-12/MPs was much higher (67).  
One of the major questions that arose from previous AR-12/MP manuscripts was how the 
administration route affected the distribution of AR-12/MPs, and how this affected AR-12/MPs 
ability to combat infections. Considering AR-12 upregulates autophagy, but does not lead to large 
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production of inflammatory cytokines to recruit other immune cells (57), it is important that AR-
12/MPs deliver drug to areas where the infection will occur. This is why intranasal F. tularensis, 
intravenous L. donovani, and intraperitoneal S. Typhi infections were combatted with intranasal, 
intravenous, and intraperitoneal AR-12/MP administrations, respectively. ICG/MPs were used to 
determine Ace-DEX vehicle trafficking because far red fluorescence has very little tissue 
background, resulting in high signal to noise ratios (68).  While no soluble ICG was used in the 
experiments presented here, it is well documented that soluble ICG clears extremely quickly and 
thus any ICG present within organs after a few hours is due to the sustained delivery of ICG/MPs 
(69). 
For intraperitoneal delivery, the highest dose of AR-12 administered was 80 mg/kg, which 
was found to be the limit of particle suspendability (Table 2.3). Due to the fact that AR-12/MPs 
could not be administered at higher doses, the dose escalation of soluble AR-12 was also stopped. 
For cancer treatment, the intraperitoneal space is seen as a very robust compartment with only a 
small number of drug related adverse events observed and thus, it is not surprising that this route 
was able to tolerate the highest dose of AR-12 (70). There was initially a large amount of ICG 
within most organs following intraperitoneal administration; however, logs of reduction following 
3 hours does not indicate an ideal long extended release. (Figure 2.4) When administered 
intraperitoneally, PLGA particles do not exhibit high levels of organ deposition either, which could 
indicate this route of administration is not ideal for sustained release of microparticulate vehicles 
within organs (71, 72).  
The intravenous route shows a modest increase in the MTD by formulation of AR-12/MPs. 
The Blank MP control has an MTD much higher than that of the AR-12/MP and thus it can be 
assumed that the MTD is drug related. In preclinical testing and the phase I clinical trials conducted 
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with soluble AR-12 as a cancer therapy, cardiac toxicity was noted as being one of the dangers of 
AR-12 (73). While there is only a small increase in the MTD through encapsulation of AR-12, it 
is a possibility that the toxicity seen is due to cardiac toxicity and thus encapsulation of AR-12 
does not result in a high degree of toxicity mitigation when administered through this route. It is 
possible that using DCM to formulate AR-12/MPs would have yielded no reduction in toxicity 
with respect to the soluble drug via intravenous administration because of the reduction in 
controlled release. Similar to the intraperitoneal administration, large quantities of ICG were 
detected in most organs directly after administration; however, within 6 hours, logs of reduction 
are seen indicating minimal controlled release. When administered intravenously, PLGA particles 
are cleared very rapidly unless modified with polyethylene glycol, which could indicate a possible 
solution for the subpar controlled release seen with Ace-DEX/MPs administered in this route (71, 
72). 
The intranasal route shows the greatest increase in the MTD by formulation of AR-12/MPs. 
The Blank MP control is very similar to the AR-12/MPs indicating that this MTD is mostly 
excipient based and not AR-12 based. The toxicity resulting from the AR-12/MPs and the Blank 
MPs is possibly physical blockage of the airways within nose and lungs which would significantly 
limit the ability for the mouse to breathe. As alveolar macrophages engulf AR-12/MPs there will 
be less AR-12 that can be released within the lung milieu and cause damage. Additionally, the AR-
12/MPs that are not phagocytosed immediately within the lungs will slowly release AR-12 over a 
period of weeks rather than the bolus administration of soluble AR-12 and thus, the concentrations 
of AR-12 that interact with all lung tissues are far larger for the soluble administration. This is 
likely why in former work, AR-12/MPs administered via the intranasal route led to enhanced 
survival with respect to soluble AR-12 following F. tularensis infection (55). Delivery via the 
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intranasal route, resulted in a large depot of ICG within the lungs for many days with steady 
clearance, rather than the log reductions seen using other routes. Even in the liver, a secondary 
deposition organ for intranasal administration, there appears to be large quantities and sustained 
delivery of ICG. The tissue accumulation of Ace-DEX particles seen via intranasal administration 
is far greater than that reported for PLGA, which only distributed throughout the lungs and bladder 
over a period of 11 days (74). Inhalational infections caused by pathogens such as F. tularensis 
have the ability to spread to other organs at high efficiency and would require the presence of AR-
12 within other organs for successful treatment highlighting the importance for multiple organ 
deposition with AR-12/MPs. 
Information regarding the efficacy and toxicity of AR-12/MPs is important to determine 
clinical translation of the formulation, but equally important is the manufacturability of the 
formulation, and the ability to sterilize AR-12/MPs. For any clinical production, microparticulate 
formulations must either be produced and sterilized, or manufactured within a clean room (75). 
There are many processes for sterilization of formulations, but gamma irradiation and ethylene 
oxide were selected because they are two of the most popular and cost effective procedures (76). 
Both sterilization techniques rendered some differential degradation and AR-12 release at pH 7.4 
(Figure 2.5); however, it took roughly 400 hours (~2.5 weeks) before these differences became 
apparent. The trafficking studies showed that there should be minimal particle loads left within 
organs after 2.5 weeks, and thus the differences in release and degradation are likely of little 
consequence. Additionally, release and degradation at pH 5.0 post sterilization are extremely 
similar, which would indicate no effect on Ace-DEX’s acid sensitivity. 
While degradation and release kinetics are important to determine following sterilization, 
the most important formulation characteristic is efficacy of AR-12/MPs after sterilization. In an in 
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vitro experiment using S. Typhi, AR-12/MPs that were sterilized via either gamma irradiation or 
ethylene oxide had significant knockdown of intracellular pathogen when compared to Blank MP 
controls (Figure 2.6). This would indicate that although there was slight modulation of release 
kinetics at pH 7.4 following sterilization, there was no effect on the AR-12 encapsulated within 
the Ace-DEX vehicle. Sterilization is known to inhibit drug delivery cargo activity, which 
validates the stability of Ace-DEX as a carrier vehicle (77).  
By improving the formulation characteristics of EE and release kinetics, there is the 
potential to improve the DCM formulation of AR-12/MPs that showed extreme promise against 
the pathogens F. tularensis, L. donovani and S. Typhi. Additionally, showing that AR-12/MPs 
reduced toxicity seen with the soluble form of the drug in vivo was paramount to making the 
argument for employing a drug delivery vehicle. Furthermore, discovering where AR-12/MPs 
traffic and persist was crucial in rationalizing why certain treatments were more successful than 
others according to route of administration. Finally, determining if AR-12/MPs can be sterilized 
was important for any clinical progression of the formulation.  
2.5 Conclusion 
Ace-DEX MPs have been shown to facilitate delivery of the host-mediated therapeutic AR-
12 to clear intracellular infections within macrophages without the resistance based complications 
of pathogen-mediated therapeutics. By using EA as the organic solvent in the emulsion 
formulation, AR-12/MP EE was increased and release kinetics were improved, which has the 
potential to enhance the efficacy of the formulation. Moreover, it was discovered that Ace-
DEX/MPs can release their cargo and escape the lysosomal compartment very quickly following 
APC internalization, which is advantageous for a host-mediated therapy carrier. Furthermore, it 
was determined that encapsulation into an Ace-DEX vehicle protects against the toxic effects of 
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soluble AR-12 in multiple routes of administration. In addition, trafficking studies elucidated Ace-
DEX MPs deposition locations when administered via the intravenous, intraperitoneal, or 
intranasal routes. Lastly, it was discovered that AR-12/MPs have the capability of being sterilized 
for clinical applications without reduction in efficacy. Through the knowledge gained from these 
experiments, there now exists a deeper understanding of the Ace-DEX platform for treating 
intracellular pathogens.  
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Figure 2.1 Scanning Electron Micrographs of Acetalated Dextran Microparticles 
Encapsulating AR-12 
Scanning electron micrographs of acetalated dextran microparticles encapsulating AR-12 (AR-
12/MPs) where the organic solvent is A) dichloromethane or B) ethyl acetate. Scale bar is 1 µm. 
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Table 2.1 Encapsulation Efficiency and Dynamic Light Scattering of AR-12 Microparticles  
Encapsulation efficiency and dynamic light scattering hydrodynamic diameter of 2% initial wt. 
acetalated dextran microparticles encapsulating AR-12 (AR-12/MPs) formulated with 
dichloromethane or ethyl acetate. 
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Table 2.2 Encapsulation Efficiency of Higher Loaded AR-12 Microparticles 
Encapsulation efficiency of acetalated dextran microparticles encapsulating AR-12 (AR-12/MPs) 
formulated with ethyl acetate at various initial weight loadings. 
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Figure 2.2 Drug Release Kinetics from AR-12 Microparticles  
In vitro drug release kinetics of AR-12 at A) pH 5.0 and B) pH 7.4 from acetalated dextran 
microparticles encapsulating AR-12 (AR-12/MPs), formulated with dichloromethane (DCM) or 
ethyl acetate (EA). Data is displayed as mean ± standard deviation (n = 3). 
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Figure 2.3 Lysosomal Escape of Particles and Cargo 
In vitro lysosomal escape of A) Coumarin-6 encapsulated within acetalated dextran microparticles 
(Coumarin-6/MPs) using Lysotracker red and B) Texas-Red conjugated Ace-DEX particles (Tx-
red/MPs) using Lysotracker green. Images are taken following 10 minutes of incubation and 
compared to Blank MP controls.  
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Table 2.3 Maximum Tolerated Dose of Different AR-12 Formulations  
Maximum tolerated dose of blank acetalated dextran microparticles (Blank MPs), acetalated 
dextran microparticles encapsulating AR-12 (AR-12/MPs), and soluble AR-12. * indicates 
maximum possible administrable dose.  
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Figure 2.4 Indocyanine Green Microparticle in Vivo Trafficking  
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Indocyanide green acetalated dextran microparticles (ICG/MPs) accumulation as reported by total 
flux [p/s] within the liver, spleen, kidneys, heart, lungs, superficial cervical lymph nodes (SCLN), 
and inguinal lymph nodes (ILN) via A) intraperitoneal, B) intravenous, or C) intranasal 
administration routes. Time points recorded were 1, 3, 6, 24, 48, 72, 120, and 240 hours. Data is 
presented as mean ± standard deviation (n = 4). 
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Figure 2.5 Degradation and Release of AR-12 from Sterilized Microparticles  
Degradation profiles of sterilized and non-sterilized blank acetalated dextran microparticles (Blank 
MPs) at A) pH 5.0 and B) pH 7.4. AR-12 release profiles of sterilized and non-sterilized acetalated 
dextran microparticles encapsulating AR-12 (AR-12/MPs) at C) pH 5.0 and D) pH 7.4. Data is 
presented as mean ± standard deviation (n =3). 
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Figure 2.6 Efficacy of Sterilized Microparticles  
Treatment of Salmonella enterica Typhi in vitro with soluble AR-12, acetalated dextran 
microparticles encapsulating AR-12 (AR-12/MPs), or blank acetalated dextran microparticles 
(Blank MPs) that were not sterilized, gamma irradiated, or ethylene oxide treated. * indicates p 
<0.05 with respect to each Blank MP group. Data is presented as mean ± standard deviation (n = 
3). 
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Chapter 3: Electrosprayed Remote Loaded Liposomes1 
3.1 Introduction 
Resiquimod (R-848) is an imidazoquinoline small molecule that is an agonist of Toll-Like 
Receptor 7/8 (TLR 7/8) (78). Due to its TLR activity, it can serve as an adjuvant in subunit 
vaccines, (79) or be applied topically to treat skin cancer, (80) genital warts (81) or cutaneous 
leishmaniasis (82). Recently, encapsulation of R-848 in both liposomes (83) and the biodegradable 
polymer acetalated dextran (Ace-DEX) (84) was reported for the treatment of visceral 
leishmaniasis. In previous work with liposomal R-848, a thin-film hydration and passive loading 
formulation technique was used to encapsulate the drug in liposomes. This method; however, 
yields only low encapsulation levels (Final weight loading of ~1.1 %) and the number of steps 
involved makes the production process difficult to scale up. Both of these issues are barriers to 
further development of this standard approach. To address these barriers, a new technique 
involving a combined remote loading and electrohydrodynamic spray (electrospray) process to 
form liposomes encapsulating R-848 was developed. 
Liposomes have been used extensively in drug delivery to formulate chemotherapeutics 
(85-87). Sterically stabilized liposomes have been shown to prolong drug circulation time by 
reducing clearing from the reticuloendothelial system (RES) (88, 89). In other studies, liposomes 
were shown to increase drug plasma concentration (i.e., area under the curve (AUC), maximum 
                                                 
1 This chapter previously appeared as an article in the Journal of Molecular Pharmaceutics. The original citation is as follows: One 
Step Encapsulation of Small Molecule Drugs in Liposomes via Electrospray-Remote Loading. Mol Pharm. 2016 Jan 4;13(1):92-
9. 
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concentration (Cmax)) enhance drug targeting to specific tissues, (90-92) and decrease drug toxicity 
(93). Usually, liposomes are passively loaded, that is the drug is mixed with the unassembled lipids 
and is incorporated into the liposome’s bilayer or inner core during self-assembly (83, 94). 
Alternatively, weakly acidic or basic drugs can be remotely loaded into assembled liposomes using 
transmembrane gradients of pH and/or various buffers (85, 95-100). In this case, empty liposomes 
are generally prepared in an initial salt or low pH buffer. The extra-liposomal phase is then 
removed using dialysis, size exclusion chromatography, or by titrating the pH to slightly basic 
conditions. Finally, the drug is added to the extra-liposomal phase and the liposomes are incubated 
to allow the remote loading process to proceed. 
Figure 3.1 illustrates schematically the key steps in the remote loading approach for a 
weakly basic amine drug and a trans-membrane ammonium sulfate gradient based on current 
literature (85, 95-100). In this case, the ammonia gradient drives a pH gradient, leading to active 
transport of the drug into the liposome. The sulfate then acts as a counter-ion for the ionized drug, 
causing it to precipitate within the liposome. This strategy has been applied to the production of 
liposomal doxorubicin in the case of Doxil® (101). Myocet® is another example of liposomal 
doxorubicin that is remote loaded, although the pH gradient is established with citric acid (85). R-
848 is a good candidate for remote loading because it has a primary amine that can act as proton 
acceptor. 
Wu et al. first reported a coaxial electrospray method to make polyplexes (102). This 
method is analogous to ethanol injection or dilution methods in the sense that the lipids are first 
dissolved in ethanol and then rapidly contacted with an aqueous phase. In the electrospray process, 
the two solutions first encounter each other in the ~0.1 mm3 liquid cone formed at the tip of the 
coaxial electrospray needle (103, 104). The jet of fluid leaving the cone is unstable and breaks up 
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to form an aerosol of the lipid-ethanol-water mixture. It is hypothesized that as the droplets travel 
toward the collection dish, the ethanol rapidly evaporates and the polyplexes are formed. Although 
the details are not completely understood, Wu et al. clearly demonstrated that the electrospray 
approach is a continuous, scalable way to generate lipid carriers.  
In this chapter, it is demonstrated that remote loading of R-848 into liposomes, produced 
by conventional thin-film hydration or electrospray, greatly increases the level of encapsulated R-
848, thereby addressing the earlier problem of limited drug loading. Furthermore, simplification 
of the production of liposomal R-848 is facilitated by combining remote loading with electrospray 
liposome fabrication. The resulting method, referred to as electrospray remote loading, is a novel 
process with the advantages of improved final drug loading, as well as ease and scalability of 
production. This approach may ultimately lead to more inexpensive, continuous production 
processes for liposomal R-848 or other drugs that can be easily remote loaded. All remote loaded 
liposomal R-848 samples were characterized for final drug loading (wt.%), in vitro drug release 
kinetics, size and morphology, and in vitro drug bioactivity using RAW macrophages. 
3.2 Materials and Methods 
3.2.1. Chemicals 
All chemicals were used as received. The following lipids were purchased from Avanti 
Polar Lipids (Alabaster, AL, USA): L-α-phosphatidylcholine from chicken egg (EggPC) and 18:0 
PC 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC). R-848 was purchased from Alexis 
Biochemicals, Enzo Life Sciences (Farmingdale, NY, USA). Cholesterol (Chol) and all other 
chemicals (unless indicated) were purchased from Sigma Aldrich (St. Louis, MO, USA). 
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3.2.1. Liposome Preparation via Thin-film Hydration 
Figure 3.2 illustrates the multi-step thin-film hydration process used to produce liposomal 
R-848 via passive or remote loading. EggPC, DSPC and cholesterol were dissolved in chloroform 
at a molar ratio of 50:20:30, respectively, to yield a solution containing 17.5 mg/mL lipids. For 
passive loading, R-848 was dissolved in the chloroform/lipid solution at a drug to lipid ratio of 
1:9. The lipid-chloroform solution is placed into a round bottom flask and the chloroform is 
evaporated off using a Buchi R-200 rotary evaporator and water bath (New Castle, DE, USA) to 
form a well-mixed thin-film of lipids upon the wall of the round bottom flask. The lipid film was 
then reconstituted in deionized (DI) water for passive loading or ammonium sulfate (250 mM) for 
remote loading and incubated for 1 hour in a 60 C water bath. Liposomes were then frozen and 
thawed 3 times by alternately submerging the solution in dry ice and the heated water bath. The 
solution was then extruded through an 80 nm polycarbonate membrane Avanti Mini-
Extruder/Heating Block 11 times to form a monodisperse population. Passive loaded liposomes 
were separated from free drug via size exclusion chromatography with a GE Healthcare disposable 
PD-10 column (Pataskala, OH, USA) and the buffer was exchanged for DI water. Remote loaded 
liposomes, in turn, were run through a disposable PD-10 column for buffer exchange into PBS 
(pH 5.25). Once a salt gradient was formed, R-848 was added to the suspension after first 
dissolving it in a small amount of ethanol and the liposomes were incubated at 30 C for 4 days. 
The remote loaded liposomes were then separated from free drug with a disposable PD-10 column 
and the buffer was exchanged for DI water. Following the removal of free R-848, sucrose (150 
wt% as a cryoprotectant) was added to both liposome suspensions, and the samples were 
lyophilized. 
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3.2.3. Liposome Preparation via Electrospray 
Two approaches were investigated using electrospray. These two methods will be referred 
to as standard electrospray and electrospray remote loading. For all electrospray experiments, the 
lipid formulation (i.e. the molar ratio of lipids used) was the same as that used in the thin-film 
hydration method. The coaxial needle setup followed that of Wu et al. (102) and consisted of a 27 
gauge inner needle and a 20 gauge outer needle. A positive voltage (~2.5 kV) was applied to the 
inner needle, with respect to the grounded copper ring positioned 0.5 cm below the coaxial needle 
tip, deforming the liquid meniscus and producing a stable concave convergent jet.26, 27 Syringe 
pumps maintained the flow through each needle at 1 mL/hr, and the aerosol was collected in 15 
mL of solution.  
In standard electrospray, the lipids, and drug were dissolved in ethanol at a lipid 
concentration of 9 mg/mL and a drug to lipid mass ratio of 1:9. The lipid solution was pumped 
through the outer needle. The aqueous phase, a 20 mM ammonium acetate buffer, was pumped 
through the inner needle. The collection solution was 10 mM PBS (pH 7.4). After spraying for 6 
hours, free R-848 was removed by size exclusion chromatography and the buffer was replaced 
with DI water. Sucrose was then added to the liposomes (150 wt% as a cryoprotectant), and the 
samples were lyophilized. 
For the electrospray remote loading process (Figure 3.3) the lipid ethanol solution (50 
mg/mL) was pumped through the inner needle and the aqueous buffer was pumped through the 
outer solution. This change was made to better mimic the ethanol injection process. I.e. liposomes 
form when the ethanol – lipid solution, flowing through the inner needle, is rapidly hydrated by 
injection into the aqueous ammonium sulfate (250 mM) solution flowing through the outer needle. 
In the electrospray process, hydration of the lipids is enhanced by the rapid evaporation of ethanol 
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from the droplets, due to the higher vapor pressure of ethanol relative to water. R-848 was 
dissolved in the PBS (pH 5.25) collection dish solution after first dissolving it in a small amount 
of ethanol. After spraying for 60 min, the collection solution was incubated at 30 C for 4 days. 
The liposomes were then separated from free drug via size exclusion chromatography with 
disposable PD-10 columns, and the buffer was exchanged for DI water. Sucrose was added to the 
liposomes (150 wt% as a cryoprotectant), and the samples were lyophilized. 
3.2.4. Final Drug Loading 
Final drug loading is defined as the mass of R-848, measured via auto-fluorescence in a 
sample, divided by the total mass of liposomal drug. To determine the final mass of liposomal 
drug, the liposome solution (after removal of free drug and buffer exchange) was placed in a pre-
weighed vial, and a known mass of sucrose (~67.5 mg) was added and dissolved in the suspension. 
After lyophilization, the vial was re-weighed and the mass of the liposomal R-848 was determined 
by mass balance. The mass of the drug was determined by dissolving the lyophilized liposomal R-
848 in methanol at a concentration of 1 mg/mL and comparing the auto-fluorescence of R-848 (ex. 
260 nm, em. 360 nm) in the sample to a standard curve based on unencapsulated R-848 dissolved 
in methanol.  
3.2.5. Dynamic Light Scattering (DLS) Particle Characterization 
DLS measurements were performed using a Brookhaven (Holtsville, NY, USA) BI-200SM 
goniometer with a laser wavelength of 633 nm, pinhole of 200 m, and a detector at 90. 
Lyophilized liposomes were reconstituted to 1 mg/mL in DI water for DLS analysis. The 
suspension was further diluted with DI water until the count rate was in a range that was acceptable 
for the instrument (10-200 kCPS). The number weighted mean particle diameter reported from 
DLS are reported as the average of the three measurements  the standard deviation.  
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3.2.6. Transmission Electron Microscopy (TEM) Particle Characterization 
TEM measurements were performed using an FEI Tecnai G2 Bio Twin TEM. Lyophilized 
liposomal R-848 was suspended in in water at 1 mg/mL and pipetted onto a clean silicone pad. 
Liposomes were loaded onto formvar/carbon-coated nickel grids by placing the grid over the 
sample droplet with the support film facing down. Liposomes were allowed to collect on the 
support film for 2 minutes, and then the excess liquid was wicked away using filter paper. Next, 
the grid was placed over a droplet of Uranyl Acetate (UA, 1 %). Negative staining with 1 % UA 
proceeded for 2 minutes and the excess liquid was wicked away. The grid was then imaged.  
3.2.7. In Vitro Drug Release Kinetics 
Release profiles were measured in sodium acetate buffer at pH 5.5 and PBS at pH 7.4, both 
at 37 C. Empty liposomes and liposomal R-848 samples were weighed, placed in microcentrifuge 
tubes, and suspended in buffer so that the concentration of liposomal drug or empty liposome was 
1 mg/mL. At defined time points, aliquots were withdrawn and placed in an Millipore (Billerica, 
MA, USA) Amicon® Ultra-4 Centrifugal Filter Unit. The filtrate was isolated, collected, and 
stored at -20°C. After all filtrate samples were collected they were brought up to room temperature 
and the auto-fluorescence (ex. 260 nm, em. 360 nm) of the R-848 was measured using a microplate 
reader. The fluorescence of the samples that contained only empty liposomes was subtracted as a 
background and the remaining intensities were used to calculate R-848 content using a calibration 
curve established with known R-848 concentrations. 
3.2.8. RAW Macrophage Cell Culture 
The in vitro bioactivity was evaluated using murine RAW 264.7 macrophages (ATCC, 
Manassas, VA). Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Hyclone 
Logan, UT) with high glucose (4.5g glucose/L), L-Glutamine, sodium pyruvate, 10 v/v% fetal 
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bovine serum (FBS; Characterized; Hyclone Logan, UT) and 1 v/v% penicillin-streptomycin. Cells 
were seeded in a 96 well plate at 5 x 104 cells per well and incubated overnight to allow cells to 
attach.  
3.2.9. RAW Macrophage Nitrite Production and Cell Viability 
 Cells were treated with free or liposomal R-848, empty liposomes, and lipopolysaccharidee 
(LPS) for 24 hours. The supernatants were removed, placed in microcentrifuge tubes and 
centrifuged at 21xg for 10 minutes to isolate the supernatant. A 50 L aliquot of each supernatant 
sample was pipetted into a new 96 well plate to quantify the amount of nitrite produced by the 
cells. A Griess assay (Promega, Madison, WI) was performed following the manufacturer’s 
directions. 
 The cells remaining in the plate were analyzed for viability. After removing the 
supernatants, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dissolved in 
medium (0.5 mg/mL) was added to the cells. The plate was incubated for ~3 hours, until dark 
purple crystals were observed. The medium was then aspirated off and isopropyl alcohol was 
added to dissolve the crystals. The absorbance was read at 560 nm and subtracted from the 
background at 670 nm.  
3.3 Results 
3.3.1. Final Drug Loading 
Table 3.1 presents the encapsulation efficiency and final drug loading of the four different 
fabrication methods. All methods used an initial drug to lipid ratio of 1:9 (or 10 wt % drug) but 
yielded different final drug loadings. In both manufacturing methods, remote loading yielded 
significantly higher levels of R-848 in the liposomes, compared to the standard methods. 
Furthermore, the level of R-848 in the liposomes produced by electrospray remote loading is 
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comparable to that in the liposomes produced by the thin-film remote loading method. Passive and 
standard electrospray liposomes were not investigated further due to their poor R-848 loading.  
3.3.2. Particle Characterization 
DLS and TEM were used to characterize the size and morphology of the liposomes. 
Liposomal R-848 size distributions measured by DLS are shown in Figure 3.4 (a), and mean 
particle diameters are 137  11 nm and 103  4 nm for samples produced by the thin-film and 
electrospray methods, respectively. The TEM images, Figure 3.4 (b) and 3.4 (c), show that 
liposomes appear to be spherical vesicles and that the sizes are consistent with the DLS 
measurements. Furthermore, as illustrated in Figure S1 of the supplemental material, DLS data 
confirm that lyophilization did not significantly change the liposome size. 
3.3.3. Drug Release Profiles 
Figure 3.5 illustrates the measured in vitro drug release profiles for both types of remotely 
loaded liposomal R-848. These profiles show the amount of drug released from the liposomes in 
buffer as a percentage of the total drug encapsulated. The error bars correspond to triplicate 
measurements of each sample at each pH (5.5 and 7.4). The initial release of R-848 proceeds 
almost linearly for the first ~6 hours. After ~10 hours, essentially no further R-848 is released. 
Electrosprayed remote loaded liposomes approach 7% total drug released after 50 hours in both 
pH 5.5 and 7.4 buffers. Thin-film hydration remote loaded liposomes approach 25% and 28% total 
drug released after 50 hours in pH 5.5 and 7.4 buffers, respectively. 
3.3.4. In Vitro Bioactivity 
The in vitro activity of liposomal R-848 prepared via thin-film hydration and electrospray 
remote loading was studied using RAW macrophages, and the resulting nitric oxide production 
levels and cytotoxicity are summarized in Figure 3.6. The control groups demonstrated the 
48 
 
expected nitrite production results: negative controls (medium only and empty liposomes) 
produced nitrite concentrations of about 1 μM, whereas the positive control (LPS) produced a 
nitrite concentration of 16 μM. At the two highest R-848 doses (0.125 and 0.250 g/mL), both 
liposomal drug formulations performed as well as, or better than, the free drug. There were no R-
848 doses for which thin-film liposomes showed a statistical increase in nitrite values with respect 
to free drug. For the electrosprayed liposomes, the liposomal drug resulted in a statistically 
significant increase in nitrite production over free drug at a dose of 0.125 µg/mL. There was no 
decrease in cell viability following incubation with either liposomal formulation at any dose. 
3.4 Discussion 
In former work, a drug loading of 1.1% wt% R-848 in liposomes produced using the thin-
film hydration and passive loading method was achieved (83). That value is comparable to the 
0.8% drug loading that is reported here for the same method, even though the liposomes in earlier 
work were prepared using hydrogenated (soy)L-a-phosphatidylcholine (HSPC) rather than the 
EggPC used in this chapter. The low solubility of R-848 in water clearly limits the amount of drug 
that can be incorporated into the aqueous volume of the liposome via passive loading. Likewise, 
passively incorporating R-848 into the phospholipid bilayer in the thin-film hydration step, only 
achieves marginal loading. In contrast, active transport of the drug and precipitation of the drug 
within the liposome means that remote loading can bypass the solubility and compatibility issues 
of passive encapsulation, to achieve high loadings. The observation that remote loading can 
increase the level of R-848 by more than a factor of 5 over passive loading, agrees with the results 
of Sur et al. (105).  
Simply implementing remote loading into the thin-film method produces a slightly higher 
drug loading than the novel electrospray remote loading method. However, the electrospray-
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remote loading method that is presented bypasses several of the time and labor intensive steps of 
the thin-film remote loading approach and provides a route to scalable production, which would 
be advantageous in an effort to make administration of liposomal R-848 economically feasible in 
a practical sense. The combination of electrospray with remote loading is novel and yields a drug 
loading that is a considerable improvement over the drug loadings previously reported for 
liposomal R-848 produced via the thin-film method with passive loading (106). As a novel method, 
there is room for optimization of drug loading efficiency in future work. However, these results 
lay a foundation for future studies with liposomal R-848. 
The sizes of the liposomes produced here are comparable to those that have been previously 
reported (75  31 nm) for liposomal R-848 (83), but slightly smaller than those made by Wu et al. 
(190  39 nm). In Wu et al.’s coaxial electrospray experiments, a mixture of lipids (including a 
charged nucleic acid condensing lipid) were dissolved in ethanol and pumped through the outer 
needle, while antisense oligodeoxynucleotide (ODN) therapeutics dispersed in buffer flowed 
through the inner needle. The size difference is possibly the result of loading payloads of two 
different sizes: ODN (a strand of approximately 600 nm in length) compared to a small molecule 
like R-848 (~1.15 nm). Moreover, the use of lipids with varying transition temperatures may have 
affected the stiffness (or bending elasticity) of the planar lipid membrane, and hence, the final 
equilibrium liposome size (107). We note that in Figure 3.4, the TEM image for liposomes 
prepared in a dried state, with the very small structures likely representing dried sucrose, which 
are not as visible in the electrosprayed liposome TEM. These structures were dissolved in aqueous 
suspension when DLS measurements were made. Thus, the two methods yielded comparable 
particle sizes in DLS.  
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One of the problems with liposomes containing EggPC is the drug retention and stability 
when stored in an aqueous environment. The European Union approved EggPC doxorubicin 
formulation, Myocet®, is prepared at the bedside due to the poor liposome stability and drug 
retention in which most of the doxorubicin is released from the liposomes in vitro within 48 hours 
(108, 109). One way to mitigate poor stability or drug retention is through the addition of a 
cryoprotectant for dry storage, rather than aqueous storage (110). Sucrose was incorporated into 
this formulation process as a cryoprotectant directly before freezing and subsequent lyophilization 
so that liposomal R-848 could be stored as a dry powder. Future studies will aim to show that dry 
storage of liposomal R-848 can increase stability and drug retention over time as compared to 
aqueous storage. 
The release kinetics for the electrospray remote loaded liposomal R-848 found that at either 
pH, only about 7% of the drug that was encapsulated in liposomes was released into the buffer. It 
is; however, not uncommon for liposomes to retain most of a small molecular drug, especially in 
the presence of a sulfate buffer such as ammonium sulfate. Fritze et al. (85), for example, reported 
only a 2 % maximal release for liposomal doxorubicin, even at pH 5.5, and hypothesized that the 
relatively low pKa of sulfuric acid (H2SO4) causes the drug to remain in its anionic form. Thus, 
our maximal release of R-848 from liposomes is consistent with published results.  
It can be observed from Figure 3.5 that thin-film hydration remote loaded liposomes 
showed a greater percent release of R-848 in both pH 5.5 and 7.4 buffers than the electrosprayed 
liposome formulation (A ~ 30% versus A ~ 7% respectively). The process of extrusion which 
sizes the thin-film hydration liposomes, involves a great deal of pressure which can lead to partial 
destabilization of the lipid bilayer (111). Both methods yielded liposomes with similar 
characteristic release times ( ~ 6 hours for thin-film hydration and  ~ 8 hours for electrospray). 
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Thus, it’s possible that the extrusion steps in the thin-film method make more of the liposomal 
drug available to release, although the release still occurs at the same rate. While the bulk of the 
drug was retained within the thin-film hydration liposomes after 50 hours, further studies are 
planned to determine if the electrosprayed remote loaded liposomes have the capacity for retaining 
their payload better than their thin-film hydration counterparts with drugs other than R-848. 
In addition to membrane integrity, liposome ultrastructure may have an effect on the 
differential drug release between thin-film hydration and electrospray remote loaded liposomes. 
The images acquired used a negative stain TEM which does not always reveal ultrastructural 
characteristics of the liposomes, such as lamellarity since the negative stain does not necessarily 
penetrate between the lipid lamellae. The difference between ultrastructure of liposomes produced 
via electrospray and conventional methods has been reported previously by Wu et al. using both 
cryo-TEM and Small Angle Neutron scattering (112). These previously published results shed 
some light on the difference between formulations; however, further research must be performed 
to understand the differences in liposomal ultrastructure between thin-film hydration and 
electrosprayed liposomes. 
Cellular responses from the in vitro experiment are encouraging since they show that the 
efficacy of the drug is not diminished by remote loading it into the liposome. This implies that the 
liposomes are releasing the drug within the cells. The results showed that the performance of the 
drug only exceeded that of free drug at the two highest doses. This observation is consistent with 
the thought that liposomes are a controlled release system and that the vehicle must be internalized 
by the cell for drug activity, since corresponding ligand for R-848 is located in the endosomal 
compartment (113). At the lower drug concentration, the rate limiting step in the activation of the 
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cell would appear to be controlled by the uptake of the liposome, which is overcome at the higher 
concentration when the cells are saturated.  
We hypothesize that the drug is retained within the liposome in the cell culture medium as 
evidenced by the retention of the drug at pH 7.4, in Figure 3.5. Upon phagocytosis, the liposomes 
will release R-848 through any number of processes as noted by Hwang et. al (114) and bind to 
intracellular TLRs 7 and 8, as implied by the production of nitrite. Since the release profiles from 
Figure 3.5 indicate that the drug is retained at pH 5.5, the results in Figure 6 imply that the pH 
change alone cannot account for the drug escape from liposomes within macrophages. Further 
studies are required to fully elucidate the mechanism of liposomal escape. However, the ability of 
the liposome to shield drug release at physiological and acidic pH may improve the safety of the 
drug, increasing the potential systemic application. Moreover, the liposomal R-848 did not cause 
statistically significant decreases in cell viability at any of the doses compared to the medium only 
controls. It is possible, that the thin-film liposomal R-848, and free drug treatments may be 
demonstrating a saturation of the toll-like receptor at high doses. However, the MTT data does not 
indicate a decrease in cell viability at these high doses, which is expected when TLR saturation is 
reached (115-117). Nitric oxide was not measured for the passive loaded liposomes because former 
manuscripts (118, 119) have reported there is evidence that the ratio of drug loaded particles to 
cells can have an impact on the ability for the drug to stimulate a response in vitro, and roughly 
five-times more passively liposomes would be needed compared to remote-loaded at any one R-
848 concentration. 
The results presented within this chapter demonstrate that a remote loading schematic to 
produce highly loaded liposomal R-848 through traditional thin-film hydration and electrospray 
methods was generated. Other scalable methods that have been developed for liposome production 
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include reverse phase evaporation (120, 121), the bubble method (122), and the French press 
method (123). The ethanol injection method (124) has been proposed as a potential method for 
scalable production of liposomal kanamycin (96, 125). Another promising approach for continuous 
and controlled liposome production is the microfluidic mixing technique of Yu et al. (126). In 
many of these methods; however, low drug loading remains a challenge, and a one step, continuous 
production method that incorporates active loading is still missing. Like the methods of Yu et al., 
our method improves on conventional liposome production by offering a route to continuous 
production. Furthermore, electrospray remote loading demonstrates the first liposome production 
process in which a scalable liposome production method is combined with active loading of a 
small molecule drug such as R-848 in essentially a single step. In addition, it was demonstrated 
that liposomal R-848 produced by electrospray remote loading can be lyophilized, reconstituted 
while retaining the same liposome size, and exhibits desired in vitro drug release and bioactivity 
profiles, thereby facilitating long term storage. 
3.5 Conclusion 
In this chapter, it was demonstrated that remote loading of liposomal R-848 through the 
highly scalable and continuous method of electrospray was possible. This method was compared 
to conventional thin-film hydration methods incorporating both passive and remote loading 
approaches. With either method, significantly higher R-848 loading was achieved by 
implementing remote loading. Moreover, for the first time, a novel process called electrospray 
remote loading, which is a one step, continuous process by which liposomes can be produced 
and actively loaded with R-848. The in-vitro release kinetics and bioactivity of the liposomal R-
848 were consistent with drug retention at physiological pH followed by intra-cellular release.  
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Additionally, the liposomal R-848 did not cause significant cytotoxicity in macrophages. 
Liposomal electrospray could also be applied to other small molecule therapeutics which can be 
actively remote loaded such as doxorubicin for scale-up production (127). 
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Figure 3.1 Remote Loading Schematic  
A schematic for remotely loading a weakly basic drug into a liposome. The reaction arrows show 
equilibrium with the larger arrow pointing to the side of the reaction that is favored. Reaction 
equations are arranged mechanistically, and the brackets, “{”, indicate when the reaction applies 
to a specific species. D stands for drug. D-N symbolizes drug that is a weak base with an amine 
group. D-NH+ is the protonated form of the drug. D-NH2SO4 is the sulfate salt precipitate that may 
be formed with the amine portion of the drug. 
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Table 3.1 Encapsulation Efficiencies for Liposomal Resiquimod  
The encapsulation efficiencies and final drug loadings measured for all four liposomal resiquimod 
preparation methods. 
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Figure 3.2 Thin-film Hydration Remote Loaded Liposome Process  
A schematic of the thin-film rehydration/extrusion technique. Frames a–e show the steps for 
passive loading in which the drug is added to the organic solvent in frame a. Frame f illustrates the 
additional steps required for remote loading. Here the drug is added as the second step of frame f. 
 
 
 
 
 
 
58 
 
 
Figure 3.3 Electrospray Remote Loaded Liposome Process  
Electrospray remote loading setup for producing liposomal resiquimod (R-848). The lipids 
dissolved in ethanol come into contact with an ammonium sulfate buffer in the coaxial electrospray 
cone-jet where the ethanol is rapidly diluted to a concentration that depends on the flow rates. 
Hydration of the lipids, by mixing and the rapid evaporation of ethanol from the aerosol, leads to 
the rapid formation of liposomes containing the ammonium salt. The lipids are collected in a dish 
containing R-848 dissolved in PBS. R-848 loading is driven by the ammonium sulfate gradient as 
discussed in Figure 3.1. After liposomal synthesis, the free drug was removed using a PD-10 size 
exclusion column following the manufacturer’s instructions. 
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Figure 3.4 Liposome Morphology and Size Distribution  
(a) Typical particle size distributions obtained from DLS for lyophilized remotely loaded 
liposomal resiquimod (R-848) prepared using both thin-film hydration and electrospray. TEM 
images of lyophilized liposomal R-848 prepared using (b) the thin-film hydration method with 
remote loading and (c) the electrospray-remote loading method. 
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Figure 3.5 Liposomal Resiquimod Release Profiles  
Drug release profiles at pH values of 7.4 and 5.5, for liposomal resiquimod produced using thin-
film hydration and electrospray remote loading. Error bars show the standard deviation of three 
replicates. The lines show a two parameter model fit to the data of the from A = A∞[(2/(1 + e
–
3.66t/τ)) – 1], where A is the percentage of encapsulated drug that has been released and t is time in 
hours. R2adjusted = 0.98 and 0.95 for the electrospray and thin-film liposomes, respectively. The two 
parameters are A∞ and τ. A∞ is the maximum % drug released at infinite time. The parameter τ is 
the characteristic time (in hours) required for A/A∞ to reach 0.95. The value 3.66 ensures that the 
model value, A, will reach 95% of the maximal value, A∞, when t = τ. 
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Figure 3.6 In Vitro Sctivation and Toxicity of Liposomal Resiquimod  
(a) Nitrite production data for macrophages treated with liposomal resiquimod prepared by 
electrospray and thin film with remote loading. * indicates statistical significance (p < 0.05) for 
liposomal resiquimod compared to free drug at the same dose. † indicates statistical significance 
(p < 0.05) compared to empty liposomes. (b) Cell viability data. None of the treatments 
significantly reduced the cell viability compared to the medium only control. 
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Chapter 4: Electrospinning of Saquinavir Containing Scaffolds for Microconfetti 
Production and Sustained Systemic Delivery2 
4.1 Introduction 
According to the World Health Organization (WHO), over 35 million people worldwide 
are living with human immunodeficiency virus (HIV). Although HIV infection rates have slowed 
in recent years, the total number of people living with HIV has continued to rise (128). The first 
Food and Drug Administration (FDA) approved drug to treat HIV, azidothymidine, became 
available in 1987 and since then over 30 other drugs have been approved (129). These HIV drugs 
fall under five classes: Nucleoside/Nucleotide Reverse Transcriptase Inhibitors, Non-NRTIs, 
Protease Inhibitors (PIs), Entry/Fusion Inhibitors, and Integrase Inhibitors (129). Unfortunately, 
singular drug therapy is insufficient for effective HIV treatment, and thus, highly active 
antiretroviral therapy (HAART) consisting of multiple drug classes is required, every day for the 
rest of the patient’s life. Since the introduction of these therapies, there has been a dramatic 
reduction in mortality and morbidity allowing patients to live longer and healthier lives (130); 
however, HAART treatment can still be rendered ineffective by the development of drug resistance 
(131).  
The formation of drug resistant HIV is usually a result of mutations within the HIV genome 
that occurs during a period of inadequate drug exposure, typically caused from poor adherence to 
                                                 
2 This chapter previously appeared as an article in the Journal Pharmaceutical Research. The original citation is as follows: 
Saquinavir Loaded Acetalated Dextran Microconfetti – a Long Acting Protease Inhibitor Injectable. Pharm Res. 2016 May 6. 
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the prescribed drug regimen (132). A recent study looking at HAART adherence showed that only 
55% of adults in North America and 77% of adults in Sub-Saharan Africa reached adequate 
adherence rates (133). Adherence rates of 95% or higher are required for successful treatments 
with singular PI-based combination therapy, which are difficult to achieve (132). Due to the 
turnover rate of HIV within infected patients, mutations that confer any selective advantage, such 
as a reduction in susceptibility to antiretroviral therapies, will result in a virus that proliferates at 
an alarming rate (134). While undergoing HAART, the chances of resistance formation are 
significantly decreased due to the multifaceted targets of the therapy; however, if resistance does 
occur during HAART, drug therapy options become limited. Unfortunately, the CDC claims that 
around 20% of patients in the United States undergoing HAART do not have suppression of viral 
loads suggesting either drug resistance or lack of adherence (135). 
Drug combinations such as the PI saquinavir (SQV) boosted with ritonavir (RTV) (136) 
have slightly increased patient adherence rates for effective treatment. Twice daily boosted SQV 
was shown to produce better adherence related pharmacokinetic profiles which allows for more 
“forgiveness” when adherence is not 100% as higher trough concentrations of SQV are maintained 
for longer periods of time (137). RTV works by inhibiting p-glycoprotein (Pgp) efflux pumps and 
cytochrome P450 3A4 to allow for larger bioavailability and a longer SQV serum half-life; 
however, due to SQVs hydrophobic nature, its gastrointestinal tract (GI tract) absorption following 
oral administration is still undesirable (133).  
 One method to increase patient compliance and thus adherence rates is to use long acting 
injectables. Long acting injectables have been used for psychiatric disorders (138), contraception 
(139) and male hypogonadism (140) to increase compliance and allow for a subsequent reduction 
in time of inadequate drug exposure. Additionally, a subcutaneous or intramuscular injectable 
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depot has the benefit of bypassing first pass metabolism, thus increasing drug bioavailability. This 
increase in drug bioavailability can drastically reduce the amount of drug required compared to an 
orally administered formulation (141). Furthermore, bypassing the GI tract is of importance as GI 
tract related adverse events are among the most common toxicities (142) reported with HAART 
that lead to regimen discontinuation (143, 144). Avoiding the GI tract discomfort associated with 
orally administered HAART could lead to better adherence rates from patients, which would 
reduce the chance of HIV resistant strain cultivation. Recently, TMC278 and GSK1265744 have 
been investigated as long acting injectables using nanosuspensions to provide a month’s worth of 
drug in a single dose (145). While these two formulations are practical from an injectable mass 
standpoint, they do have some undesirable characteristics. One such characteristic is the non-
tunable release kinetics because the hydrophobic interactions between drug and surfactant 
determine the rate of drug release and cannot be altered unless the drug or surfactant are changed 
(146). While long-term release is the goal, nanosuspensions can release drug for up to 12 months 
so if any site related toxicity or drug-drug interactions occur, the only option is to surgically 
remove the depot from the tissue. Additionally, depot drug concentrations remain extremely high 
even after serum drug concentrations have dropped below detection limits meaning there is slow 
and incomplete nanosuspension dissolution (147). Finally, nanosuspensions are not viable options 
for a large portion of HIV positive individuals who live in Sub-Saharan Africa because they are 
typically unstable outside of the cold-chain leading to uncharacterized release rates (148). This is 
particularly troubling as roughly 70% of all HIV positive individuals live within sub-Saharan 
Africa according to the WHO (128).  
To help create a more manageable system without some of the side-effects observed with 
nanosuspensions, a biodegradable polymer known as acetalated dextran (Ace-DEX) that can 
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overcome the need for cold-chain storage was applied. It was previously demonstrated that protein 
encapsulation within Ace-DEX alleviated the need for cold chain storage, and maintained protein 
bioactivity at elevated temperatures (42). Ace-DEX is derived from FDA-approved dextran and is 
made hydrophobic by forming acetal groups in place of hydroxyl groups along the glucose rings 
of the parent dextran molecules. Short reaction times create a larger percentage of acyclic acetals, 
which are the kinetically favorable product of the reaction. Extending the reaction time increases 
the amount of cyclic acetals, which resist hydrolytic cleavage better than acyclic acetals, allowing 
for more sustained polymer degradation in aqueous environments (36, 37). By shifting the reaction 
time, the degradation rate of polymer can be effectively tuned from days to weeks in pH-neutral 
extracellular conditions (37). Our group has used electrospun Ace-DEX scaffolds for temporal 
release of therapeutics to be used as a topical, or surgically implantable long acting release vehicle 
(149). Since that work, our group has become interested in taking advantage of Ace-DEX’s high 
glass transition temperature (~160-190°C) (42) to process these long fibers into smaller injectable 
constructs. Polyesters such as poly lactic-co-glycolic acid (PLGA), polycaprolactone (PCL) and 
poly lactic acid (PLA) are typically used for electrospinning (150); however, their glass transition 
temperature is around 50°C and limits their ability to be processed post spinning (151, 152).  
In the chapter, it is demonstrated that electrospun Ace-DEX scaffolds, unlike PCL and 
PLGA scaffolds, can be successfully processed into dispersible, high drug content injectables 
(termed Ace-DEX microconfetti (Ace-DEX-MC)) for long acting release. Ace-DEX scaffolds 
containing SQV at high loadings can be turned into MC. Saquinavir microconfetti (SQV-MC) can 
release drug at variable rates according to polymer degradability and loading, and release drug in 
vivo for more than a week from a single injection.  
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4.2 Materials and Methods 
4.2.1. Chemicals 
A majority of the materials were purchased from Sigma Aldrich (St. Louis, MO, USA) and 
used without further modifications. Saquinavir was purchased from Proactive Molecular Research 
(Alachua, FL, USA). Water was purified using a Millipore Milli-Q integral water purification 
system (Billerica, MA, USA).  
4.2.2. Ace-DEX Synthesis from 71 and 500kDa Dextran 
Ace-DEX polymer was synthesized using 71 or 500kDa dextran from Leuconostoc 
mesenteroides with some modifications to the previously described protocol(37). To synthesize 
71kDa Ace-DEX, lyophilized 71kDa dextran (1.0 g) and pyridinium p-toluenesulfonate (0.0617 
mmol) were dissolved in 10 mL of anhydrous dimethyl sulfoxide (DMSO). To synthesize 500kDa 
Ace-DEX, lyophilized 500kDa dextran (0.5 g) and pyridinium p-toluenesulfonate (0.0308 mmol) 
were dissolved in 8 mL of DMSO. Dissolved dextrans were reacted with Waterstone 2-
ethoxypropene (Carmel, IN, USA) under nitrogen gas at room temperature for the desired duration 
to achieve 37 or 52% relative cyclic acetal coverage, which is referred to as fast and slow degrading 
Ace-DEX, respectively. After the desired length of reaction, reactions were quenched with an 
excess of trimethylamine (TEA). While the acetalation process will result in increased molecular 
weights greater than 71 and 500kDa, it will still be referred to as 71 and 500kDa Ace-DEX in this 
work. The reaction volumes were then precipitated in basic water (.04/99.96% v/v TEA and Water 
respectively), and centrifuged at 14,500 rpm for 10 min at 4°C using a Thermo Scientific sorvall 
legend XTR centrifuge (Waltham, MA, USA) to remove any remaining water-soluble 
polysaccharides (i.e., un-acetalated dextran and/or lowly acetalated dextran). The resulting pellet 
was then frozen and lyophilized overnight. To further purify the polymer, the product was 
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dissolved in ethanol and centrifuged at 14,500 RPM for 10 min at 4°C the following day. The 
supernatant was precipitated in basic water, centrifuged again, frozen and lyophilized to yield 71 
or 500kDa Ace-DEX polymer. The extent of cyclic acetal formation was determined using 1H 
nuclear magnetic resonance (NMR) spectroscopy based on a previously developed method (37). 
4.2.3. Optimization of 71 and 500kDa Ace-DEX Electrospinning 
Ace-DEX scaffolds were first generated by dissolving 71 or 500kDa Ace-DEX at various 
concentrations in a hexafluoroisopropanol (HFIP), n-butanol, and TEA solution (59.5/39.5/1.0% 
v/v/v). When fully dissolved, the solution was loaded into a Hamilton gaslight glass model 1001 
syringe (Reno, NV, USA) and a Hamilton metal hub blunt point needle (Reno, NV, USA) was 
attached. When fully primed, the syringe was loaded onto an Analytical West Inc. scientific lab 
supply syringe pump (Lebanon, PA, USA). The syringe needle was connected to a positive voltage 
and a flat sheet of aluminum foil was connected to a negative voltage on a Gamma High Voltage 
Research power supply (Ormond Beach, FL, USA). When flow was initiated at 1mL/hr from the 
syringe pump, a voltage difference of roughly 15 kV was used to break the surface tension of the 
droplet and force the droplet into a Taylor cone. Following scaffold collection, small representative 
samples were adhered to Ted Pella aluminum specimen mounts (Redding, CA, USA) using carbon 
tape. Images were acquired using either an FEI NOVA NanoSEM 400 located at The Ohio State 
University, or a Hitachi S-4700 Cold Cathode Field Emission Scanning Electron Microscope 
located at the University of North Carolina.     
4.2.4. Production of Ace-DEX, PLGA and PCL Microconfetti 
Scaffold production of either 71 or 500kDa Ace-DEX was performed at the optimal 
electrospinning concentration as described above. Ace-DEX scaffolds were removed from the 
aluminum foil sheet and transferred to a Kyocera CM-10 BK ceramic grinder (Costa Mesa, CA, 
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USA) for processing into microconfetti (MC). Additional Ace-DEX scaffold samples were 
transferred to a Retsh 10 mL stainless steel grinder jar (Newton, PA, USA) that had been cooled 
in liquid nitrogen for 10 minutes. The loaded stainless steel grinder jar was then placed into a Glen 
Mills high speed mixer mill (Clifton, NJ, USA) and run for 5 minutes at 10 Hz for processing into 
MC. Other Ace-DEX scaffold samples were sent to Retsch (Newton, PA, USA) to be processed 
into MC using a cryomill (5 minutes precool, 5 minutes at 15 Hz). All MC samples were imaged 
using SEM as described above.  
50:50 PLGA (50-70kDa) was dissolved in a solution of HFIP and n-butanol (80/20% v/v), 
loaded into a syringe and electrospun onto aluminum foil at 1mL/hr using a voltage difference of 
20kV. PLGA scaffolds could not be processed using the ceramic grinder. Additional PLGA 
scaffold samples were transferred to a stainless steel grinder jar that had been cooled in liquid 
nitrogen for 10 minutes. The high speed mixer mill was run for 5 minutes at 10 Hz. Following high 
speed mixer milling, the sample was removed and imaged using SEM.  
PCL (70-90 kDa) was dissolved in pure chloroform, loaded into a syringe and electrospun 
onto aluminum foil at 3mL/hr using a voltage difference of 20kV. PCL scaffolds could not be 
processed using the ceramic grinder nor high speed mixer mill. Scaffold samples were sent to 
Retsch to be processed using a cryomill. Following cryomilling, samples were imaged using SEM.    
4.2.5. Production of Saquinavir loaded 71 and 500kDa Ace-DEX Microconfetti 
Ace-DEX scaffolds were generated by dissolving 71 or 500kDa Ace-DEX (400 or 200 
mg/mL, respectively) with the desired amount of SQV (10, 20, 30, 40 or 50% wt/wt) in a solution 
of HFIP, n-butanol and TEA (59.5/39.5/1.0% v/v/v). The SQV Ace-DEX scaffold was then 
allowed to dry under N2 gas for 5 minutes to ensure all solvents had evaporated. The scaffold was 
then processed using the ceramic grinder to yield SQV-MC and stored at -20ºC until further use.  
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4.2.6. Encapsulation Efficiencies of SQV-MC 
Following generation of Ace-DEX SQV-MC, encapsulation efficiencies were determined 
by preparing a 1mg/mL solution of SQV-MC dissolved in high performance liquid 
chromatography (HPLC) grade methanol and MilliQ water (80/20% v/v). These samples were 
analyzed using an Agilent Technologies Series 1100 HPLC (Santa Clara, CA, USA) with an 
Agilent Eclipse Plus C18 column (4.6 x 150 mm) at a flow rate of 1mL/min, injection volume of 
60 µL and a detection wavelength of 240 nm alongside a standard curve of un-encapsulated SQV. 
The drug elution time was ~6 minutes, and following the HPLC run, the amount of encapsulated 
SQV was determined.  
4.2.7. SQV-MC In Vitro Release Curves 
Briefly, 71 and 500kDa SQV-MC samples were suspended at a concentration of 2 mg/mL 
with 0.01% v/v Tween 80 (specific gravity = 1.06) in phosphate-buffered saline (PBS) at pH 7.4. 
Once in suspension, varying quantities, dependent on SQV loadings, were placed into Thermo 
Fisher Scientific snakeskin dialysis bags with an 8kDa cutoff, (Grand Island, NY, USA). The 
dialysis bags (n = 3 per time point), were placed into 1L beakers with PBS on a Thermo Fisher 
Scientific RT2 advanced hotplate (Grand Island, NY, USA) set to 37ºC. As the drug released from 
the SQV-MC, it passed through the dialysis membrane into the PBS sink. At each time point, 
individual dialysis bags were removed from the beaker and 200 mL of PBS sink was emptied to 
keep a constant dialysis bag to PBS volume ratio. Residual SQV-MC was removed from the 
dialysis bag by washing with excess basic water. This was then centrifuged at 4,000 RPM for 10 
minutes at 4ºC to pellet any residual SQV-MC. The supernatant was removed, and the pelleted 
SQV-MC was frozen and lyophilized. At the final time point, one additional sample was suspended 
in 0.01% v/v Tween 80 in PBS (pH 7.4), placed in a dialysis bag and then removed like every 
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other sample. This specimen represented a “0 hour” time point release. Following sample 
lyophilization, all samples were dissolved in 3mL of HPLC-grade methanol and Milli-Q water 
(80/20% v/v) and analyzed using the HPLC method outlined for encapsulation efficiency. Percent 
SQV release was then calculated relative to the “0 hour” data point. 
4.2.8. In Vivo Release of SQV-MC 
ICR mice (female, 8-10 weeks old) were purchased from Taconic Farms (Hudson, NY, 
USA). The two groups consisted of 71kDa fast degrading 10 and 30% SQV-MC. 8 mg of each 
SQV-MC was injected (266 mg of polymer/kg) equating to roughly 26.6 and 80 mg/kg of SQV, 
respectively. SQV-MC was suspended in 0.01% v/v Tween 80 in PBS (pH 7.4), mice were placed 
under light anesthesia using isoflurane, and 300 µL was injected into the subcutaneous space (left 
flank). Collection time points were 20 minutes, 1 day, 3 days and 7 days post injection. At each 
time point, mice (n = 2) were euthanized in a CO2 chamber followed by cardiac puncture to collect 
blood. Serum was then obtained by centrifuging the blood samples in Becton Dickinson 
microtainer heparin lined tubes (Franklin Lakes, NJ, USA) for 5 minutes in a VWR mini centrifuge 
(Radnor, PA, USA) and freezing it on dry ice. The spleen, liver, kidney and brain were also 
harvested and rapidly frozen in liquid nitrogen. All samples were then stored at -80ºC until 
quantification.   
4.2.9. LC/MS Quantification of Serum and Tissue Samples 
Following extraction from the mice, serum and tissue samples were analyzed for SQV 
content based on previously published work (153). The quantity of SQV in samples was 
determined using Sciex Analyst Chromatography Software on a Sciex API-5000 triple quadrupole 
(Foster City, CA, USA) Liquid Chromatography Mass Spectrometry (LC/MS) machine. 
Calibration curves were obtained by using a weighted linear regression of analyte:internal standard 
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peak area ratio vs. concentration curve. The quantity of SQV within each sample was determined 
from this calibration curve. 
4.3 Results 
4.3.1. Optimization of 71 and 500kDa Ace-DEX Electrospinning 
Ace-DEX scaffolds were created by electrospinning 71 and 500kDa Ace-DEX using an 
HFIP, n-butanol and TEA solution. Concentrations well below the optimal spinning concentration 
of 200 and 400 mg/mL for 71 and 500kDa, respectively, led to more erratic Taylor cone stability 
and yielded pseudo fiber-particle combinations (Figure 4.1 a and d). At concentrations closer to 
the optimal spinning concentration, undesirable spindly fibers with fewer intermittent particles 
were observed (Figure 4.1 b and e). At optimal spinning concentrations of 400 and 200 mg/mL for 
71 and 500kDa Ace-DEX, respectively, homogenous ribbon-like fibers were seen (Figure 4.1 c 
and f). 
4.3.2. Production of Ace-DEX, PLGA and PCL Scaffold Microconfetti 
Ace-DEX scaffolds had a fluffy texture and were easily removed from aluminum foil 
whereas PLGA and PCL scaffolds were more rigid and more difficult to collect. Processed PLGA 
(high speed mix mill) and PCL (cryomill) scaffolds were completely fused (Figure 4.2 a and b). 
The fused PLGA made collection from the jar difficult even after cooling the high speed mixer jar 
in liquid nitrogen. Cryomilled PCL formed small powdery aggregates without well-defined 
structures. Ace-DEX-MC generated by high speed mixer milling and cryomilling were a fine 
powder of small fractured fibers of relatively polydisperse size (Figure 4.2 c and d). The ribbon 
fiber morphology was retained throughout the grinding process and minimal, if any, fusion was 
seen. Ace-DEX-MC generated with the ceramic grinder was a fine powder of large fractured fibers 
72 
 
of relatively polydisperse size (Figure 4.2 e and f). The ribbon fiber morphology was retained 
throughout the grinding process and minimal, if any, fusion was observed. 
4.3.3. Encapsulation Efficiencies of SQV-MC 
Due to the large quantities of SQV required, care was taken to ensure all solids were in 
complete solution before proceeding to electrospinning. All Ace-DEX SQV-MC was loaded at 
extremely high efficiency with the lowest encapsulation efficiency being 98.2% (Table 4.1). The 
consistent drug loading (from initial to final) demonstrates this. 
4.3.4. 71kDa SQV-MC In Vitro Release Curves 
In vitro release profiles were generated to determine the release kinetics of SQV-MC 
depending on SQV weight loading and Ace-DEX polymer degradation rate (Figure 4.3 a, b, c and 
d). All samples exhibited a burst release of SQV within the first two hours followed by relatively 
linear release afterwards. As drug loading in fast degrading Ace-DEX-MC increased, so too did 
burst release of SQV. With slower degrading Ace-DEX, however, there was no clear trend as burst 
release values remained fairly consistent across SQV loadings. Throughout all samples, it was seen 
that increasing the drug loading increased the release of SQV at 24 hours. In fact, with the 40% 
SQV-MC, there was greater than 50% SQV release within the first 24 hours. Throughout all 
samples, the slower degrading Ace-DEX showed a more sustained release of SQV even when 
increasing the SQV loading.  
4.3.5. 500kDa SQV-MC In Vitro Release Curves 
In vitro release profiles were generated from the higher molecular weight SQV-MC to 
determine if higher loading could be achieved with similar release patterns (Figure 4.4). Both the 
slow and fast degrading Ace-DEX exhibited a burst release of SQV within the first 2 hours 
followed by relatively linear release afterwards. Similar to the 71kDa SQV-MC, an increase in the 
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cyclic acetal coverage led to a reduction in the degradation rate of Ace-DEX and a more sustained 
release. Interestingly, the 50% 500kDa SQV-MC released SQV at a slower rate than the 40% 
71kDa SQV-MC using both the fast and slow degrading Ace-DEX polymers.  
4.3.6. In Vivo Release 
Serum concentration-time profiles were generated by taking time points at 20 minutes, 1, 
3 and 7 days post injection (Figure 4.5). 20 minutes’ post-injection demonstrated a large burst 
release of SQV into the serum for both groups (67.45 and 144.5 ng/mL for 10 and 30% SQV-MC, 
respectively). Following the initial burst of SQV, there was a fairly linear release of SQV into the 
serum for both the 10 and 30% SQV-MC injection groups. However, on day 7, the 10% SQV-MC 
injection exhibited a spike in serum concentration which boosted the serum concentration to 32.9 
ng/mL. 
Tissue SQV concentrations were analyzed from the 30% SQV-MC injection group at 20 
minutes, 1, 3 and 7 days post-injection (Figure 4.6). There was not any detectable SQV within the 
brain at any time point. Twenty minutes after injection, there was SQV within both the kidneys 
and liver (42.6 and 33.8 ng/mg respectively), however, SQV was undetectable within the spleen. 
SQV concentrations remained fairly stable within the liver over the duration of the 7 day study. 
One day after injection, accumulation within the kidneys and spleen drastically increased (315 and 
179 ng/mg, respectively). Following the high concentration within the kidney and spleen on day 
1, the concentrations dropped slightly 3 days post injection and concentrations approached baseline 
levels 7 days post injection. 
4.4 Discussion 
It has been reported that upwards of 20% of HIV positive patients within the United States 
are infected with strains that confer at least partial resistance to one or more available treatments 
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with increases of more than 5% annually for at least one class of HIV therapies (154). The lack of 
adherence to HAART within the infected community could mirror the complications faced with 
treatments against other resistant pathogens (e.g., Staphylococcus aureus (155) and 
Mycobacterium tuberculosis (MTB) (156)). Long acting drug delivery systems have the ability to 
overcome the resistance complications associated with non-adherence as they enable fewer 
administrations within the dosing regimen. In this chapter, the novel, highly loaded and tunable 
injectable release system of Ace-DEX-MC for the sustained delivery of SQV was investigated. 
It was possible to electrospin homogenous ribbon-like fibers of both 71 and 500kDa Ace-
DEX scaffolds by increasing the concentration of polymer within the solvent system to 400 and 
200 mg/mL, respectively, as seen in Figure 4.1. The ribbon morphology observed here is due to 
the highly volatile solvent system which evaporates quickly causing a polymer fiber shell to 
collapse on itself (157). During the electrospinning process, the polymer, drug and solvent system 
travel through the air to a grounded plate. As they travel, the solvent system evaporates leaving 
the polymer to harden into fibers containing the drug. Due to the fact that there is no external liquid 
continuous phase, such as the water that is commonly used in emulsion particle formulations (118), 
drug remains within the fibers which leads to the high encapsulation efficiencies (Table 4.1). 
Furthermore, it has been reported that when a drug is not readily soluble within the electrospinning 
solution, drug crystals are visible within the fibers and lead to a substantial burst release of drug 
even at low drug loadings (158). Considering SQV has relatively good solubility within our solvent 
system, this is not an issue and drug crystals are not seen on the fibers.  
Due to electrospun scaffolds’ ability to encapsulate drug at high loadings, they are desirable 
for extended drug delivery. Highly loaded polymeric scaffolds have been used to treat stenosis 
through surgical implantation (159); however, this is highly unfavorable and impractical for 
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frequent (e.g., weekly or bi-weekly) treatments. Long acting injectables such as Risperdal® 
Consta® microparticles can have encapsulation efficiencies as low as 20%, which wastes a large 
quantity of drug (160). This can be further problematic for drugs that are not very potent, as these 
low encapsulation efficiencies lead to final weight loadings of ~12-15% which require extremely 
high polymer doses for any given treatment. For example, SQV requires 2 g or greater for daily 
oral dosing (4% bioavailability without RTV), so a long acting injectable for weekly doses at 
loading similar to Risperdal® Consta® could require greater than 5 g of polymer, when currently 
the maximum amount of polymer in an injectable is 1.2 g for Vivitrol® (161). One of the hallmarks 
of the injectable nanosuspensions TMC278 and GSK1265744 is that the drug content is ~80% by 
weight and the drugs themselves are extremely potent allowing for minimal excipient load (145). 
However, the cold chain storage requirements significantly limit the usage of these treatments 
within the developing world, especially within sub-Saharan Africa where cold chain storage is not 
readily available (162). As previously mentioned, Ace-DEX has the ability to maintain cargo 
stability at elevated temperatures alleviating cold chain requirements that are often needed for 
other biopolymers such as PLGA (42), which further strengthens the wide applicability of SQV-
MC. Future studies will analyze SQV-MC release kinetics and bioactivity after storage at elevated 
temperatures.  
SQV is known to be more effective within Tcells than within macrophages suggesting that 
SQV can be readily oxidized in oxidative environments, diminishing its activity (163). While the 
activity of SQV has not been affected by incubation with H2O2 (164), SQV is highly oxidized via 
cytochrome P450 3A4 and thus there exists the possibility of losing efficacy when stored in oxygen 
rich environments. Future studies will determine if encapsulation within MC has the ability to 
protect SQV from oxidation and preserve activity.  
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Because polymer scaffolds require surgical implantation and current FDA-approved long-
acting formulations have manufacturing and storage concerns, the optimal system design is highly 
loaded Ace-DEX scaffolds that can be processed into an injectable formulation called MC. As 
mentioned previously, Ace-DEX has a glass transition temperature of roughly 160-190°C (42) 
while PLGA and PCL are closer to 50°C (151, 152). When PLGA or PCL scaffolds are processed 
using a high speed mixer mill or cryomill, respectively, the MC from these polymers fuse to form 
large aggregates (Figure 4.2). This occurs because a significant amount of local heat is generated 
when the ball impacts the jar (165). As the heat transfers into the PCL and PLGA materials, the 
temperature rises above their glass transition and changes their physical structure from rigid to 
amorphous which causes fusion. We have previously shown that microparticulate Ace-DEX can 
resist agglomeration at elevated temperatures while PLGA microparticles do not (42). Slight 
agglomeration of Ace-DEX fibers was accomplished by grinding scaffolds with a mortar and 
pestle; however, this technique was not used any further. Ace-DEX has the capability to be 
processed into MC of different sizes depending on the energy of the grinding procedure as seen 
within Figure 4.2. When using the high speed mixer mill and cryomill (high energy processes), 
smaller MC fragments were created which could be used for intracellular delivery of therapeutics 
as these MC fragments would be readily engulfed by phagocytes, similarly to the elliptical disks 
used by Champion et al. (166). The ceramic grinder created larger fragments which are 
advantageous for sustained delivery to systemic circulation, as objects larger than 10 µm in length 
will effectively evade phagocytic uptake (167). Future research will be performed to determine the 
degree at which ceramic grinder-processed MC resist phagocytosis. Since the goal is to actively 
deliver drug into systemic circulation over an extended period of time, the larger MC generated by 
the ceramic grinder was investigated.  
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  Another advantageous characteristic of Ace-DEX is its tunable hydrolytic degradation 
rates that are simply based on the synthesis reaction time and subsequent cyclic acetal coverage. 
Polysaccharides such as dextran, used for controlled drug delivery are noted to release cargo via 
diffusion and/or dissolution (168). As seen in Figures 4.3 and 4.4, the rate of SQV release from 
SQV-MC can be increased by decreasing the cyclic acetal coverage, which subsequently increases 
the degradation rate of the polymer. Because SQV is a fairly hydrophobic drug with a log P value 
of ~ 1.9 (169), it will prefer to reside within the hydrophobic polymer matrix rather than diffusing 
into the aqueous environment. Upon hydrolysis, the fiber will begin to erode and SQV will be 
released. With the faster degrading Ace-DEX-MC, there is a substantial burst release followed by 
a less drastic sustained release from all loadings and polymer molecular weights. We believe this 
large burst release occurs because of a combination of drug located on the surface of the fibers, 
and the smaller number of cyclic acetals (larger number of acyclic acetals) leads to more extensive 
initial hydrolysis, allowing for rapid fiber dissolution. Alternatively, the slow degrading Ace-DEX 
has a drastically smaller burst release, likely due to the fact that far more of the acetal groups are 
cyclic acetals limiting the hydrolysis of the polymer within the first few hours in an aqueous 
solution and for the duration of release. While there is a small burst with the slower degrading 
Ace-DEX, this likely comes from the drug located on the surface of the MC. Due to the fact that 
SQV is released predominantly through polymer degradation/dissolution, complete drug release 
from implanted PLGA scaffolds could take weeks to months. In fact, Crow et al. have shown that 
drug release from PLGA fibers can have half-lives of greater than 9 weeks (170). The slow SQV 
release kinetics that PLGA would likely exhibit might lead to inadequate serum concentrations. 
Since PLGA cannot be processed into injectable MC, surgical implantation would be required, 
making PLGA very undesirable for this application. 
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There is a clear trend that with increased loading, the drug will release more quickly from 
both the fast and slow degrading Ace-DEX groups. This most likely stems from the fact that as the 
drug content within the fiber increases, the polymer matrix within the fiber becomes more unstable 
with reduced polymer entanglement that would restrict drug release. Interestingly, the 71kDa 40% 
SQV-MC releases drug faster than even the 500kDa 50% SQV-MC with both the fast and slow 
degrading Ace-DEX. We believe this occurs because at the weight loading of 40% with 71kDa 
Ace-DEX, SQV is close to the solubility limit in our solvent system. Indeed, the Taylor cone 
generated from these electrospinning conditions was less stable than the other samples, perhaps 
indicating that not all of the components were completely dissolved. When the molecular weight 
is increased to 500kDa the solution becomes more viscous, allowing for a smaller polymer 
concentration required for stable Taylor cone formation, thus leading to a lower SQV 
concentration needed for fabrication (i.e., a weight loading of 50% using 500kDa Ace-DEX has a 
SQV concentration of ~200mg/mL in the solvent system). 
To analyze the ability of SQV-MC to be used as a sustained delivery vehicle, ICR mice 
were injected subcutaneously with the fast degrading 71kDa 10 and 30% SQV-MC. The fast 
degrading Ace-DEX was selected because mice are known to have faster systemic circulation 
clearance rates than humans (171) and slow releasing SQV-MC might not release drug fast enough 
for sufficient serum and tissue accumulation. In fact, the total systemic clearance of SQV is around 
4.81 L/h/kg in mice (172) and 1.14 L/h/kg in humans (173). 8 mg of each MC formulation was 
injected which contained 0.8 and 2.4 mg SQV for 10 and 30% SQV-MC respectively. 8mg of 
SQV-MC was selected because it was more than likely that different masses of polymer would 
lead to differential degradation and release rates independent of the SQV loading. The 
subcutaneous administration route was selected considering Gautam et al. have shown that the 
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subcutaneous space was satisfactory for release of antiretrovirals and enables a larger injection 
volume than does the intramuscular space (174).  
For the 30% SQV-MC, a large burst was seen after injection resulting in high 
concentrations of SQV within the serum. This was not surprising as the polymer will begin 
degrading following introduction to an aqueous environment, and any surface SQV would likely 
be released instantaneously. Following the burst release from SQV-MC into the serum, the serum 
levels of SQV steadily decline as the clearance rate of SQV out of circulation was likely faster 
than the release rate of SQV from the MC. It is conceivable that high serum concentrations of SQV 
in humans could be achieved for much longer than they were in the ICR mice due to the drastic 
differences in typical SQV clearance rates in each species. The 10% SQV-MC saw a large burst 
almost instantaneously, similar to the burst seen with the 30% SQV-MC followed by a steady 
decline in serum SQV concentrations. Interestingly, there was an unexpected secondary burst of 
SQV from the injection depot following 3 days of release. We believe this secondary burst is the 
result of a sudden degradation of a pocket of SQV-MC within the depot. The secondary burst 
phenomenon has previously been reported when using PLGA microspheres for sustained release 
of a hydrophobic PI which suggests that it could possibly be related to drug cargo (175). The 
concentration at which 90% of viral growth is inhibited (IC-90) for SQV is noted to be anywhere 
from 3 to 50 ng/mL in serum (173) which is reached during the majority of the one week timeframe 
with the 30% SQV-MC but not with the 10% SQV-MC. However, with a 4-fold lower clearance 
rate within humans, it is possible that concentrations above the IC-90 could be reached for a longer 
duration than was shown within this study. Future studies plan to use larger groups and use longer 
durations for release with SQV-MC. 
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When adhering to the proper HAART regimen, serum viremia can be controlled; however, 
HIV still has the ability to develop reservoir infection sites in the brain, spleen, gastrointestinal 
tract, lymphoid tissue and other organs in which there is differential drug distribution allowing for 
increased chances for resistance (176). Tissue accumulation of SQV was analyzed following 
release from the 30% SQV-MC in the same mice that had their serum samples analyzed. As can 
be observed in Figure 4.6, there is an initial accumulation peak of SQV within the tissues following 
one day of release from SQV-MC followed by a steady drop in the tissue content of SQV until 7 
days when there are very low levels of tissue SQV. SQV is not privy to crossing the blood brain 
barrier as has previously been reported (177), most likely due to high Pgp activity at the blood 
brain barrier interface. It was our initial hypothesis that constant release of SQV into circulation 
could potentially overwhelm the available Pgp pumps allowing for some accumulation, but that 
action was not achieved. PI’s like SQV have recently been noted for inducing significant 
hepatotoxicity within HIV positive individuals (177). This may be explained by SQV 
predominantly being metabolized within the liver by cytochrome P-450 3A4 (178) as well as direct 
passage to the liver after oral delivery of conventional formulations. SQV accumulation within the 
liver of our mice was lower than the drug amounts in all organs other than the brain. Thereby, our 
formulation should reduce the concentration of SQV that reaches the liver, compared to current 
oral formulations. Future work will focus on determining if constant SQV release from SQV-MC 
leads to elevated aspartate aminotransferase levels, indicative of hepatotoxicity as well as how 
these levels compare to the oral formulation.  
Before the HAART era, HIV patients displayed white-pulp depletion within their spleens 
(179), which signifies significant T-cell reduction, increasing the chances for opportunistic 
infections such as bacterial pneumonia, MTB and many others (129). Since the induction of 
81 
 
HAART in the mid-1990s, life expectancy, quality of life and the risk of opportunistic infections 
have dramatically improved confounded with a conservation of white-pulp within HIV patient’s 
spleens indicating the importance of the spleen within the HIV infection process (179). It has been 
reported that the spleen contains close to 15% of the total lymphocytes in the body (greater than 
any other organ) which are the primary targets of HIV (180). It is therefore significant that the 
spleen was able to accumulate a large quantity of the SQV released from SQV-MC as this is a 
likely reservoir organ for the virus, and as a number of antiretroviral drugs accumulate poorly 
within the spleen (180).  
 It has been widely documented that SQV has the ability to increase the occurrence of renal 
calculi (kidney stones), however, no renal toxicity has been attributed to SQV (181). The largest 
quantity of SQV released from SQV-MC was detected within the kidneys which is interesting, 
because typically less than 1% of SQV is excreted from the kidneys (173). The small percentage 
of renal excretion probably stems from the drastic first pass metabolism that occurs when SQV is 
dosed orally, meaning that SQV-MC could radically change the amount of non-metabolized SQV 
that reaches other organs. The quantity of SQV within the kidneys is meaningful, because HIV 
can cause nephropathy due to viral replication within the kidney (182). In fact, HIV has been 
detected within podocytes, parietal cells and renal tubular cells at high levels highlighting the 
ability of HIV to cause kidney damage and the subsequent importance of drug delivery to the 
kidney (183).  
One aspect which was not investigated within this work is to boost SQV with RTV as is 
performed within the clinic (184, 185) which can lead to an increase in the orally administered 
area under the curve and Cmax of SQV by over 50 and 22 fold, respectively (186). The potential to 
increase the serum concentrations and allow for passage through the blood brain barrier and testes 
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using RTV could be coupled with the slow degrading SQV-MC, allowing for sustained delivery 
over a longer period of time than was achieved in the current study. A longer sustained release 
period from Ace-DEX-MC would lead to fewer required administrations and would cut down on 
the potential for non-adherence related complications. Additionally, if the serum concentrations 
are increased for a longer duration, it is likely that there will be a larger accumulation of SQV 
within the tissues (187) allowing for enhanced anti-viral activity throughout many of HIV’s tissue 
reservoirs.  
4.5 Conclusion 
A novel, highly loaded delivery vehicle for the long acting release of saquinavir into systemic 
circulation to counteract adherence related resistance in the treatment of HIV has been generated. 
Stable and relatively uniform fiber generation along with high encapsulation efficiencies of drug 
was shown. Most interesting, is the ability to process our scaffolds into injectable MC and fine 
tune the release kinetics by changing the Ace-DEX carrier polymer’s hydrolytic stability (cyclic 
acetal coverage) and total drug loading. These flexible options are unique to Ace-DEX and not 
possible with more ubiquitously used biodegradable polymers like PLGA. Finally, our work 
suggests that Ace-DEX-MC presents a platform by which other hydrophobic small molecule drugs 
can be loaded and released over time for enhanced pharmacologic effect.    
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Figure 4.1 Scanning Electron Micrographs of Acetalated Dextran Scaffolds  
Scanning electron micrographs with scale bar indicating 5 μm for electrospun constructs fabricated 
from 71 kDa acetalated dextran (Ace-DEX) at a concentration of (a) 200 mg/mL, (b) 300 mg/mL 
and (c) 400 mg/mL, and 500 kDa Ace-DEX at a concentration of (d) 100 mg/mL, (e) 150 mg/mL 
and (f) 200 mg/mL. 
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Figure 4.2 Scanning Electron Micrographs of Microconfetti Formulations  
Scanning electron micrographs with scale bar indicating 10 μm of (a) poly lactic glycolic acid 
(PLGA), (b) polycaprolactone (PCL), (c–e) 71 kDa acetalated dextran (Ace-DEX) and (f) 500 kDa 
Ace-DEX scaffolds processed by (a, c) high speed mixer milling, (b, d) cryomilling or e, (f) 
ceramic grinding. 
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Table 4.1 Drug Loading and Release Kinetics for Various Microconfetti Formulations  
Initial Weight Loading, Encapsulation Efficiency, Final Weight Loading and In Vitro Release 
Half-Lives of Saquinavir (SQV) at pH 7.4 for SQV Loaded Microconfetti Composed of 71 and 
500 kDa Acetalated Dextran (Ace-DEX) Polymer with Either Fast or Slow Degrading Properties 
(37 and 52% Cyclic Acetal Coverage, Respectively) 
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Figure 4.3 In Vitro Saquinavir Release Profiles with 71 kDa Microconfetti  
In vitro saquinavir release profiles performed at pH 7.4 for drug loaded microconfetti composed 
of fast or slow degrading (37 and 52% cyclic acetal coverage, respectively) 71 kDa acetalated 
dextran with different drug weight loadings: (a) 10%, (b) 20%, (c) 30% and d) 40%. Data are 
presented as mean ± standard deviation (n = 3). 
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Figure 4.4 In Vitro Saquinavir Release Profiles with 500 kDa Microconfetti  
In vitro saquinavir release profiles performed at pH 7.4 for microconfetti with a drug weight 
loading of 50%, composed of fast or slow degrading (37 and 52% cyclic acetal coverage, 
respectively) 500 kDa acetalated dextran. Data are presented as mean ± standard deviation (n = 3). 
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Figure 4.5 Serum Saquinavir Concentrations Following a Single Administration  
Mice were injected subcutaneously on the left flank with fast degrading (37% cyclic acetal 
coverage) 71 kDa acetalated dextran microconfetti loaded with 10 and 30% SQV by weight. Serum 
samples were collected at the presented time points and concentrations of saquinavir (SQV) 
following in vivo release were analyzed. Data are presented as mean ± standard deviation (n = 2). 
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Figure 4.6 Tissue Saquinavir Concentrations Following a Single Administration  
Mice were injected subcutaneously on the left flank with fast degrading (37% cyclic acetal 
coverage) 71 kDa acetalated dextran microconfetti loaded with 30% SQV by weight. Tissue 
samples were collected at the presented time points and concentrations of saquinavir (SQV) 
following in vivo release were analyzed. Data are presented as mean ± standard deviation (n = 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
 
Chapter 5: Electrosprayed Acetalated Dextran Microparticles for Vaccine Applications 
5.1 Introduction 
Vaccines are widely regarded as the most efficient way to prevent death from infectious 
disease worldwide (188). Prophylactic vaccinations have been utilized since the Chinese used 
inoculation techniques against Smallpox around 900 AD; however, live attenuated vaccines 
contain whole pathogen, and are known to cause dramatic toxicity and can even result in death 
(189). In contrast, subunit vaccines generate fewer adverse events than their live attenuated 
counterparts. A subunit vaccine contains only a portion of a pathogen, termed an antigen, which 
allows the host to develop a specific immune response towards the pathogen without the negative 
components of whole pathogen that are contained within live attenuated vaccines. 
For a subunit vaccine to be effective, the antigen must be internalized by antigen presenting 
cells (APCs) within the host and subsequently presented to Tcells. The interaction between APCs 
and CD8+ Tcells is mediated through the major histocompatibility complex (MHC) class I 
molecule and is required for cellular immunity. APCs and CD4+ Tcells interact through MHC 
class II molecules and is required for humoral immunity. Dendritic cells (DCs) are widely 
recognized as professional APCs and thus, the interaction between DCs and Tcells dictates the 
adaptive immune responses towards a specific antigen (190). There are fail-safes within the 
immune system to regulate antigen presentation and activation of Tcells, or else autoimmune 
diseases would occur more frequently. The fail-safes for APCs are considered co-stimulatory 
signals, which are upregulated when pathogen associated molecular patterns (PAMPs) or danger 
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associated molecular patterns (DAMPs) bind to pathogen recognition receptors (PRRs) within 
APCs to alert the DC to the presence of a foreign pathogenic substance (191). In the absence of 
co-stimulatory signaling, effector Tcells will not become highly activated, even if MHC molecules 
containing antigen are presented. Thus, because subunit vaccines often contain minimal PRR 
binding substances, they can lack efficacy generating robust adaptive immune. To improve the 
efficacy of subunit vaccines, adjuvants are often utilized, which can induce innate immune 
responses.  
Adjuvants play critical roles in enhancing the immunogenicity of many vaccines, and are 
particularly important for subunit vaccines, which are poorly immunogenic on their own. While 
existing adjuvants such as aluminum salts (alum) have proved to be effective inducers of potent 
Th2 biased responses and humoral immunity, they frequently fail to induce significant Th1 
responses that drive protective cellular immunity against intracellular pathogens. Because most 
adjuvanted vaccines use only one adjuvant, and they are nearly all Th2 skewing, subunit vaccines 
cannot be broadly applied to all pathogen types.  
The use of more than one adjuvant in a vaccine formulation could improve the protective 
responses a vaccine generates. An example of a multi-PRR stimulating vaccine is the yellow fever 
17D (YF-17D) vaccine.  The Food and Drug Administration (FDA) approved live attenuated YF-
17D vaccine is one of the most effective vaccines known to date in its more than 50 years on the 
market. It was recently discovered that the YF-17D vaccine activates multiple toll-like receptors 
(TLRs) within DCs to generate broad spectrum innate immune responses for potent Th1 and Th2 
balanced immune response (192). The multiple and broad stimulation of the YF-17D yields a 
potent vaccine that only needs to be administered once for life-long protection (188). While YF-
17D represents a potent live attenuated immune stimulator with multi-PRR activation capabilities, 
92 
 
an adjuvant system that can target multiple, well-defined PRRs that could be partnered with a 
subunit antigen would be more beneficial as it would enable broad vaccine applications. There is 
a clear need for potent adjuvant combinations that simultaneously stimulate various immune 
targets, which could lead to fewer boosts or smaller quantities of administered antigen.  
Combination adjuvant systems have shown the ability to generate synergistic responses, in 
which there is greater immune activation with a combination than either adjuvant administered by 
itself (193). The most notable combination adjuvant, termed AS04, was recently FDA approved 
and contains TLR-4 agonist monophosphoryl lipid A (MPL) and Alum. These adjuvants activate 
the immune system through separate signaling pathways and generate a balanced immune response 
that can be crucial for intracellular pathogens. However, this remains the first and only FDA 
approved combination adjuvant system. Additionally, the mechanisms of interaction between the 
two adjuvants is poorly understood (194).  
A combination of adjuvants with well-defined pathways is needed to form a potent vaccine. 
A newly discovered immune pathway, stimulator of interferon genes (STING), generates a robust 
Th1 skewing immune response which can lead to successful cellular immunity that is required for 
intracellular pathogen vaccines, and has broad implications for combinations with TLR agonists 
due to unique activation pathways (195). STING activation generates production of type I 
interferons, which induces activation of DCs through increased expression of MHC class I and II 
molecules, co-stimulatory signals, as well as allows for enhanced priming of CD4+ and CD8+ 
Tcells (196). One ligand which binds directly to and activates STING, known as 3’,3’ cyclic GMP-
AMP (cGAMP), generates robust transcriptional activation of the type I interferon pathway (196). 
While cGAMP is noted as being a potent STING agonist, the cellular membrane is a formidable 
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obstacle to overcome for this charged small molecule, as the STING pathway is located within the 
cytosolic space.  
 Despite the advantages to adjuvant systems, in vivo delivery for even a single adjuvant to 
APCs at high efficiencies can be difficult (197). Additionally, combination adjuvant systems 
delivered to interact with multiple PRRs must be delivered concurrently as those that are not 
administered at the same time have been shown to induce Tcell tolerance rather than synergistic 
activation (198). To overcome the delivery complications of adjuvant systems, drug delivery 
vehicles can be used to enhance delivery efficiency to APCs. With drug delivery vehicles, particle 
size is a critical vehicle parameter, as particles with diameters larger than 200 nm will passively 
target only phagocytic APCs but not other cells (44). Moreover, biodegradable polymeric vehicles 
have long been employed to solve delivery complications with vaccines. The most clinically 
relevant biodegradable polymer, poly lactic-co-glycolic acid (PLGA), has been investigated 
extensively as a vaccine carrier (199, 200); however, disadvantages such as slow degradation rates 
within phagosomal compartments of APCs and acidic degradation byproducts limit the efficacy of 
PLGA vaccines (201). To overcome the shortcomings of PLGA, our lab uses the newly 
synthesized acetalated dextran (Ace-DEX) biopolymer, which is derived from the FDA approved 
water-soluble polysaccharide dextran. Ace-DEX is unique due to the simplicity of its synthesis, in 
which acetal groups are formed along the glucose backbone of dextran, making the polymer acid 
sensitive and organic-soluble (36). In aqueous environments, acetal groups are hydrolytically 
cleaved, generating pH-neutral and biocompatible degradation byproducts ethanol, acetone and 
dextran. Ace-DEX can be formulated into particles for size dependent delivery to APCs, and will 
rapidly degrade over a period of hours within the low pH lysosome, with sustained degradation 
over a period of days to weeks at physiological pH (36). Ace-DEX has shown its exceptional 
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capabilities as a vaccine formulation by enhancing survival following Anthrax and Burkholderia 
pseudomallei challenge, respectively (22, 202, 203). 
To illustrate the increased efficacy of Ace-DEX formulation, Ace-DEX microparticles 
(MPs) encapsulating cGAMP (cGAMP MPs) were generated, resulting in a stable and potent 
induction of type I IFN responses (204). In a mouse model, cGAMP MPs showed dose sparing 
and enhanced protection against a lethal influenza challenge compared to soluble cGAMP; 
however, because only a single adjuvant was used, it is likely that larger quantities of antigen and 
more boosts would be required to generate the same humoral and cellular responses as a synergistic 
combination adjuvant system.   
It has become evident that new combination adjuvant systems need to be investigated for 
enhanced vaccine efficacy. This chapter investigates the formulation of cGAMP MPs using 
multiple techniques in combination with other adjuvants for synergistic potential. The optimal 
adjuvant system containing cGAMP MPs was determined at an appropriate adjuvant ratios and 
formulated into a single delivery vehicle. An in vitro comparison of single adjuvant and 
combinational adjuvants using Ace-DEX and PLGA was performed. The adjuvant systems also 
were compared in vivo to determine the degree of immune system enhancement.  
5.2 Materials and Methods 
5.2.1. Chemicals  
All materials were purchased from Sigma Aldrich, unless otherwise indicated. Vaccine 
grade cGAMP was purchased from Invivogen. 
5.2.2. Synthesis of Acetalated Dextran 
Acetalated dextran (Ace-DEX) was synthesized according to Kauffman et al. using dextran 
from Leuconostoc mesenteroides (molecular weight = 71 kDa) (37). After rapidly hydrolyzing the 
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polymer in 10% v/v deuterium chloride in deuterium oxide, its relative cyclic acetal coverage was 
determined to be 40% using 1H-nuclear magnetic resonance (NMR) spectroscopy on an Inova 400 
MHz spectrometer. 
5.2.3. Microparticle Fabrication by Electrospray 
cGAMP MPs, resiquimod (R-848) MPs, cGAMP and R-848 co-encapsulated within the 
same MP (Combo MPs) and multiple fluorophore MPs with Ace-DEX or PLGA were fabricated 
by a coaxial electrohydrodynamic spraying (electrospray) method using a Rame-Hart Instrument 
Co (Succasunna, NJ, USA) customized stainless steel needle. The MPs were collected on a 
McMaster Carr (Elmhurst, IL, USA) stainless steel plate. The needle and plate were charged with 
opposite polarities using Gamma High Voltage Research, Inc. (Ormond Beach, FL, USA) high 
voltage power sources. Avanti Polar Lipids (Alabaster, AL, USA) egg phosphatidylcholine 
(EggPC) was added post-fabrication to increase the water-suspendability of the MPs. 
5.2.4. Microparticle Fabrication by Solvent Evaporation 
cGAMP MPs, R-848 MPs, and Combo MPs with Ace-DEX or PLGA were fabricated using 
a modified version of the water-in-oil-water emulsion followed by solvent evaporation method 
reported previously (205). 
5.2.5. Endotoxin Assay 
The endotoxin content of and MPs was measured according to Gallovic et al. (205). All 
MPs had an endotoxin content of less than 0.25 EU/mL, within the recommended levels for subunit 
vaccine formulations (206). 
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5.2.6. Scanning Electron Microscopy 
MPs were placed on carbon tape attached to Ted Pella, Inc. (Redding, CA, USA) aluminum 
pin stubs and sputter-coated with 10 nm of AuPd. Electron micrographs were acquired using an S-
4700 scanning electron operating at an accelerating voltage of 2.0 kV. 
5.2.7. Cell Preparation 
Murine BMDCs used in MP stimulation and co-culture systems were prepared as described 
previously (207). Briefly bone marrow was obtained from C57BL/6 mice, were washed, and 
seeded with media containing Peprotech (Rocky Hill, NJ, USA) recombinant mouse GM-CSF. 
After 7 days non-adherent cells were seeded in GM-CSF free media overnight prior to treatment.  
5.2.8. ELISA 
ELISA kits for murine IL-6 and TNF were purchased from BD Biosciences (San Jose, CA, 
USA) and IFN-γ was purchased from Biolegend (San Diego, CA, USA). All ELISAs were 
performed according to manufacturers’ instructions. IFN- was detected by ELISA using murine 
specific IFN- antibodies from Santa-Cruz (Dallas, TX, USA).  
5.2.9. In Vitro Screening of Soluble Adjuvants in Combination with cGAMP MPs 
Bone marrow derived dendritic cells (BMDCs) from C57BL/6 mice were harvested, and 
used on culture day 9. Cells were deprived of growth factors overnight, then left untreated (Blank) 
or treated with soluble Murabutide (10 ug/ml), MPL (1 ug/mL), Poly (dA:dT) (10 ug/mL), CpG 
(1 ug/mL), Poly (I:C) (10 ug/mL) or R-848 (0.01 ug/mL). All adjuvants were purchased from 
Invivogen (San Diego, CA, USA) and cultured alone or in combination with cGAMP MPs (1 
ug/mL total cGAMP), or an equivalent amount of Blank MPs. Cell supernatants were collected 22 
hours later and were analyzed for TNF, IL-6, IL-1β, IL-12p70 and IFN-β (n=4 ± SEM). 
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5.2.10. Flow Cytometry of Multiple Fluorophore MPs  
BODIPY 493/503 (FITC channel), Texas Red (Texas Red channel), and BODIPY 630/650 
(APC channel) (All purchased from Thermo Fisher Scientific (Grand Island, NY, USA)) were 
sprayed within a single particle using the co-axial electrospray set up as described above. Particles 
were suspended in FACs buffer and flow cytometry was run using a Becton Dickinson (Franklin 
Lakes, NJ, USA) LSR II flow cytometer located at University of North Carolina at Chapel Hill. 
Blank MPs were used to generate a gated population.    
5.2.11. Quantification of cGAMP and R-848 Loading within Microparticles 
cGAMP loading was determined using high performance liquid chromatography (HPLC). 
cGAMP MPs or Combo MPs were suspended in HPLC-grade water, and a 1:1 v:v amount of 
dichloromethane was then added. This mixture was vortexed for 2 minutes and centrifuged for 45 
minutes at 15,000 x g at 4°C. An aliquot of the water phase was injected into an isocratic 80/20 
v/v water/methanol mobile phase operating at 0.6 mL/hr. After passing through a Thermo Fisher 
Scientific (Waltham, MA, USA) Aquasil C18 column, 150 x 4.6 mm, the absorbance of the eluent 
was measured at 256 nm. A standard curve of cGAMP dissolved in water was subjected to the 
same conditions, and the cGAMP loading in the MP (µg cGAMP / mg solids) was determined. 
Blank MPs subjected to the same process were used as a background correction. 
R-848 loading was determined using a plate reader for auto-fluorescence. R-848 MPs or 
Combo MPs were dissolved in dimethyl sulfoxide (DMSO) at a concentration of 1 mg/mL and 
comparing the auto-fluorescence of R-848 (ex. 260 nm, em. 360 nm) in the particle samples to a 
standard curve based on unencapsulated R-848 dissolved in DMSO and the R-848 loading in the 
MPs (µg R-848 / mg solids) was determined. Blank MPs subjected to the same process were used 
as a background correction.   
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5.2.12. cGAMP and R-848 Release Profiles 
cGAMP MPs and Combo MPs were suspended in PBS (pH 7.4) at 37°C on a shaker plate 
operating at 200 rpm. At predetermined time points, aliquots were removed and centrifuged (30 
min at 21,000 x g, 4°C). The pellets were subjected to the same process as the protocol used to 
determine cGAMP loading in MPs. Blank MPs collected at each time point were subjected to the 
same process and used as background subtractions. 
R-848 MPs and combo MPs release was performed under the same conditions as cGAMP 
release. The supernatant was placed into a 96 well plate and frozen at -20°C until all time points 
were removed. Then the 96 well plate was read on the plate reader, similar to the protocol used to 
determine R-484 loading in MPs. Blank MPs collected at each time point were subjected to the 
same process and used as background subtractions. 
5.2.13. Animals and Immunization 
All studies were conducted in accordance with National Institutes of Health guidelines for 
the care and use of laboratory animals and approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina. All animals were maintained in specific pathogen-
free facilities and were between 8 and 15 wk of age. Age and sex matched C57BL/6 mice were 
obtained from Jackson Laboratories. 
Mice were immunized on days 0, 21, and 35. Intramuscular (i.m.) injections were 
performed with PBS, 10 μg of low endotoxin ovalbumin (Ova) (Invivogen, San Diego, CA, USA) 
plus the indicated amount of particles. Alum controls were injected with antigen plus Alhydrogel 
2% (Invivogen) mixed at a 1:1 ratio by volume. 
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5.2.14. Antibody Specific Endpoint Binding Titers 
Antigen specific serum antibody binding titers (endpoint) were determined by standard 
ELISA similar to previously described methods (208). Two-fold serial dilutions of test sera were 
performed in 384-well plates coated with Ova at 2.5 g/mL and blocked for two hours at room 
temperature using carbonate bicarbonate buffer with 3% (w/v) non-fat dry milk. Plates were 
incubated overnight at 4°C then washed four times with PBS plus 0.1% Tween-20. Southern 
Biotech (Birmingham, AL, USA) Horseradish peroxidase-conjugated anti-Mouse Ig specific 
antibodies were added to plates at a 1:4,000 dilution. Plates were then incubated at room 
temperature for two hours and washed four times. TMB peroxidase substrate solution was then 
added to the plates. Following 10 minutes at room temperature, 2N H2SO4 solution was added to 
stop the reaction. The plates were read at an optical density (OD) of 450 nm using a Perkin Elmer 
(Waltham, MA, USA) Victor3 plate reader. The endpoint was set at three times the average plate 
background OD. Log endpoint titer is reported as the log of the reciprocal of the highest serum 
dilution at which the OD value was equal to or greater than endpoint. 
5.2.15. ELISPOT and Splenocyte Restimulation 
Splenocytes were isolated from mice that were immunized as described above. Thermo 
Fisher Scientific IFN-γ ELISPOTs were performed according to manufacturer’s instructions using 
2 x 105 splenocytes stimulated with 10 μg/mL Anaspec (Fremont, CA, USA) SIINFEKL peptide 
for 36 hours. Plates were dried and spots were quantified using an AID (Strassberg, Germany) 
ELISPOT Reader System. Alternatively 2 x 105 splenocytes were stimulated with 10 μg/mL whole 
OVA protein for 36 hours. Supernatants were collected and analyzed for IFN-γ by ELISA. 
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5.3 Results 
5.3.1. Combinatorial Screening of Adjuvants with cGAMP MPs In Vitro 
 Evaluation of synergistic potential was performed with cGAMP in combination with other 
adjuvants. Soluble MPL, CpG, and R-848 showed the greatest potential for synergy when 
combined with cGAMP MPs (Figure 5.1). In particular, co-administration with R-848 resulted in 
the greatest increase in TNF, IL-6, and IL-12p70 production by BMDCs. IL-1β production was 
increased by the largest margin when cGAMP MPs were co-administered with MPL. No adjuvant 
combination was able to increase the production of IFN-β when administered with cGAMP MPs 
over cGAMP MPs by themselves.  
5.3.1. Encapsulation of cGAMP and R-848 in Emulsion based Particles 
Emulsion based, solvent displacement MPs were formulated to determine if encapsulation 
efficiencies (EEs) of cGAMP and R-848 would remain constant when combining the two 
molecules within the same formulation. Table 5.1 shows that EE of cGAMP and R-848 in 
singularly encapsulated particles was 52 and 8% respectively. When encapsulating them into the 
same vehicle, R-848’s EE remained the same; however, cGAMP EE dropped in half to 24%. 
cGAMP encapsulated poorly into PLGA particles made by emulsion, so an emulsion combination 
was not analyzed for EE.  
5.3.2. Flow Cytometry of Multiple Fluorophore MPs  
To determine if multiple adjuvants could be loaded into a single particle via co-axial 
electrospray, BODIPY 493/503, Texas Red, and BODIPY 630/650 were encapsulated together. 
These electrosprayed particles were run on flow cytometry, and it was determined that the only 
particle populations that existed contained high levels of all three dyes (Figure 5.2).  
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5.3.3. Morphology, Encapsulation, and Release Kinetics of cGAMP MPs and R-848 MPs 
via Electrospray Formulation  
Formulating cGAMP and R-848 in singularly encapsulated MPs through co-axial 
electrospray yielded spherical, fairly monodisperse particles (Figure 5.3 A and B) with high EEs 
(Table 5.2). In fact, the EEs of 94 and 86% for cGAMP and R-848, respectively, are much higher 
than when formulating through an emulsion based system. Release kinetics of cGAMP and R-848 
MPs were very similar with a large burst occurring within the first 30 minutes of incubation, 
followed by a sustained release for the duration of the experiment (Figure 5.3 C).  
5.3.4. In Vitro Activity of cGAMP and R-848 MPs to Determine Optimal Ratio 
To determine the optimal ratio of cGAMP to R-848, separately encapsulated particles were 
incubated together with BMDCs (Figure 5.4). In all cytokines measured, there were robust 
responses for both adjuvants when combined at higher doses. For most cytokines measured, there 
was a clear dose-dependent response for each adjuvant. A 10:1 ratio was the most potent within 
this experiment.  
5.3.5. Morphology, Encapsulation and Release Kinetics of Combo MPs  
Combo MPs containing a targeted 10:1 initial ratio of cGAMP and R-848 in the same 
formulation were co-axially electrosprayed. The morphology of Combo MPs was different from 
that of the cGAMP or R-848 MPs in that they have an erythrocyte-like morphology rather than 
being completely spherical (Figure 5.5 A). While encapsulation efficiencies did drop, the drop was 
fairly moderate compared to the emulsion formulation. The actual ratio of cGAMP: R-848 was 
measured as 11:1 (Table 5.3), very close to the target ratio of 10:1. The release profile of each 
adjuvant was very similar to the release of the singularly encapsulated particles. There was a large 
burst occurring within the first 30 minutes of incubation, followed by a sustained release for the 
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duration of the experiment. The release kinetics following the burst release of the Combo MP was 
faster in a pH 7.4 solution than the singularly encapsulated particles (Figure 5.5 B). 
5.3.6. In Vitro Activity of Combo MPs  
To determine if co-encapsulation of cGAMP and R-848 in the same particle improved efficacy in 
vitro, they were tested at various doses. Combo MPs, a combination of singularly encapsulated 
cGAMP and R-848 MPs, or combination of soluble adjuvants were incubated with BMDCs, and 
ELISAs were run to detect secreted cytokine production (Figure 5.6). Dose-dependent cytokine 
profiles were observed for all groups. Data indicated there was a clear enhancement of cytokine 
responses when the adjuvants were encapsulated within the same vehicle for IFN-γ, IL-1-β, IL-6, 
and TNF; however, IL-12p70 was produced in larger quantities with the soluble combination.  
5.3.7. Activity of Combo MPs Formulated with Ace-DEX or PLGA Vehicles 
Combo MPs were superior to a combination of singularly encapsulated cGAMP and R-848 
MPs when using Ace-DEX polymer. Combo MP using Ace-DEX polymer were compared to 
Combo MP using the more clinically applicable PLGA polymer. At various doses, Combo MPs 
of PLGA and Ace-DEX were incubated with BMDCs, and ELISAs were run to detect cytokine 
production (Figure 5.7). IFN- β, IL-1-β, IL-6, and TNF all showed dose dependence and were 
superior with the Ace-DEX formulation; however, IL-12p70 showed higher responses with PLGA. 
5.3.8. In Vivo Antibody Titers  
Mice were vaccinated on day 0 against the model antigen Ova with either 200 ng of 
cGAMP, 18 ng of R-848, a combination of 200 ng of cGAMP and 18 ng of R-848, Alum, or Blank 
MPs. On day 21, mice were boosted with another round of injections and then on day 28, serum 
was collected and analyzed for antibody titers (Figure 5.8). PBS and Ova groups showed no Ova 
specific IgG, IgG1, or IgG2c titers at the time points measured. Blank MPs formulated from Ace-
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DEX showed much higher IgG and IgG1 titers than Blank MPs formulated from PLGA; however, 
neither blank particle generated any IgG2c titers. R-848 MP alone vaccination resulted in only a 
small increase in IgG and IgG1 titers over the Blank MPs, but it did generate IgG2c titers. cGAMP 
MP vaccination generated more IgG, IgG1, and IgG2c titers than R-848 MPs and Blank MPs. A 
combination of singularly encapsulated cGAMP and R-848 MPs showed only a slight increase in 
generation of IgG with respect to cGAMP MPs only; however, it did result in an increase in IgG2c 
and IgG1 titers. Combo MPs formulated with PLGA resulted in a modest increase in IgG titers 
with respect to cGAMP MPs formulated with Ace-DEX and resulted in an increase in IgG1 and 
IgG2c titers, similar to the combination of singularly encapsulated cGAMP and R-848 MPs. 
Finally, Combo MPs formulated with Ace-DEX showed a large increase in IgG, IgG1, and IgG2c 
titers with respect to cGAMP MPs and all other groups, including Alum. No other group resulted 
in a greater than 2.5 fold increase in total IgG with respect to cGAMP MPs except for Combo MPs 
formulated with Ace-DEX, which resulted in over a 7.5 fold increase (Figure 5.8 B).   
5.3.9. CD4+ and CD8+ Tcell Responses Following Combination Adjuvant Vaccination  
To elucidate CD8+ and CD4+ Tcell responses for combination adjuvants, mice were 
boosted a second time on day 35 and euthanized on day 42. Following splenocyte extraction, CD8+ 
Tcell responses were quantified following stimulation with SIINFEKL, the CD8+ 
immunodominant peptide of Ova, and an ELISPOT assay was performed to determine the amount 
of IFN- γ produced (Figure 5.9 A). CD4+ Tcell responses were quantified by stimulating 
splenocytes with whole Ova protein and running an IFN- γ ELISA on the supernatants (Figure 5.9 
B). Combo MPs formulated with PLGA showed CD8+ Tcell activation with ~250 IFN-γ spots 
within the ELISPOT experiment, but CD4+ Tcell activation was no higher than the Blank MPs 
formulated with PLGA. The combination of singularly encapsulated R-848 and cGAMP MPs 
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resulted in potent CD8+ Tcell activation with ~400 IFN-γ spots within the ELISPOT experiment, 
and a small IFN-γ response within the ELISA experiment. Combo MPs formulated with Ace-DEX 
were far superior to all other groups with ~400 IFN-γ spots within the ELISPOT experiment, and 
a large IFN-γ response within the ELISA experiment indicating strong CD8+ and CD4+ Tcell 
responses, respectively. 
5.4 Discussion 
In previous work, Ace-DEX MPs encapsulating cGAMP were safe, potent inducers of 
type-I interferon and vaccination with cGAMP MPs protected mice against a lethal influenza 
challenge with dose sparing over the soluble form of cGAMP (204). cGAMP MPs alone generated 
high levels of IFN-β, IL-6 and TNF (204), which are all key contributors in generating a robust 
immune response; however, cGAMP MPs lack the ability to produce IL-1β and IL-12p70 which 
are critical during viral infections and play pivotal roles in generating adaptive immune responses 
(209, 210). To broaden the cytokine profile of a cGAMP MP vaccine, and improve dose sparing, 
a combination adjuvant vaccine was investigated with the hopes of generating more potent 
responses. 
TLR and nucleotide binding oligomerization domain-like receptors (NLR) agonists are 
extremely popular as adjuvants within vaccines (211); however, MPL is the only adjuvant that was 
tested in combination with cGAMP MPs in Figure 5.1 that is FDA approved. Not only was R-848 
more potent than MPL, with a ~100 fold smaller dose being utilized within the in vitro assay, but 
it was shown to synergize at a higher efficiency with cGAMP MPs. R-848 is an imidazoquinoline 
agonist of TLR-7/8 with potent myeloid differentiation primary response gene 88 (MyD88) 
dependent transcriptional activation of NFκB pathways. The use of R-848 in a microparticulate 
vaccine in humans is relevant as TLR-7 and TLR-8 are predominantly expressed in important 
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APCs such as plasmacytoid dendritic cells, myeloid dendritic cells and monocytes (212). R-848 
has previously been shown to have synergy in vivo with a TLR-3 agonist, which is MyD88 
independent (213), which suggested that R-848 and cGAMP would have synergistic potential in 
vivo.  
A common emulsion based method was used in the first attempt to formulate Combo MPs 
of cGAMP and R-848. The EE of cGAMP dropped from 52 to 24%, which would not lead to 
viable formulation production. Additionally, R-848 EE was only 8% which would mean that a 
large percentage of the drug would be lost during each generated particle batch. Currently, 
formulation of polymeric MPs encapsulating multiple therapies is typically performed using the 
solvent evaporation technique, and while certain parameters can be modified to enhance EE of 
therapies, a target ratio is extremely difficult to repeatedly formulate (199). Furthermore, emulsion 
based solvent evaporation formulation is a batch to batch process which can result in 
inconsistencies in loading, high cost for scale up and can be difficult to produce in aseptic 
environments that could limit the potential for clinical applications (214). More recently, dual 
impinger technology has become increasingly popular in which two phases are pumped together 
simultaneously with turbulent flow to generate particles; however, an external aqueous phase is 
still a driving force for poor EE (215). To increase EE of cGAMP and R-848 within Ace-DEX 
MPs, and generate particles using a more scalable process, an alternative method known as co-
axial electrospray was utilized to formulate particles. 
Co-axial electrospray is a formulation process in which a polymer dissolved in an 
immiscible and volatile organic solvent is pumped through a co-axial needle to interact with a 
separate water phase that contains a water-soluble adjuvant. As the two phases interact at the tip 
of the co-axial needle, they form a droplet. A voltage drop is generated to break the surface tension 
106 
 
of the droplet, which forces it into an aerosol jet. As the jet projects small droplets into the air, the 
volatile organic solvent evaporates and the polymer solidifies as it travels to the collection plate. 
Because the only external phase is air, the water-soluble adjuvants will not leave the polymer and 
thus the drug in the water phase is retained within the polymer at high efficiencies (202). 
Additionally, particles generated through co-axial electrospray can be generated with diameters of 
1-3 µm, which is advantageous for passive targeting of DCs, as particles greater than 400 nm are 
more likely to be phagocytosed by DCs (216). In previous work, multiple components were loaded 
into Ace-DEX MPs via co-axial electrospray; however, ability to co-encapsulate both components 
within a single particle was not analyzed (202). Before formulating cGAMP and R-848 into co-
axial electrospray particles, a proof-of-concept MP containing multiple fluorophores was sprayed 
to ensure the formulation technique was capable of loading multiple small molecules into the same 
particle. According to Figure 5.2, all three fluorescent small molecules were distributed throughout 
the entire particle population at high levels which is an ideal formulation characteristic (217).  
The optimal ratio of cGAMP to R-848 was found to be 10:1 as it was shown in Figure 5.4 
that this ratio allowed for the highest production of pro-inflammatory cytokines. It is also of note, 
that although the other ratios of cGAMP to R-848 were not as potent as 10:1, they resulted in far 
more cytokine production than BMDCs treated with the same dose of cGAMP MPs alone (204). 
The ability to target a specific drug ratio and create a particle population with both drugs at these 
ratios with minimal drug loss, is a highly advantageous formulation strategy. Once the ratio was 
selected and the Combo MPs were analyzed in comparison to combination of singularly 
encapsulated particles in vitro, it was revealed that there was an advantage to having the adjuvants 
within the same particle. This expands upon the concept of drug delivery in which a single 
molecule can become more efficacious when delivered to a cell rather than getting to a cell on its 
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own. In this application, multiple therapeutics can be delivered within the same vehicle at fixed 
ratios to the same target allowing for highly potent delivery.  
Ace-DEX is an ideal delivery vehicle for adjuvants with intracellular targets such as 
STING and TLR-7/8 because of its acid sensitive degradation kinetics (38). Once an Ace-DEX 
particle is phagocytosed by an APC, the particle will rapidly degrade within the low pH 
environment of the lysosome. According to the release profiles in Figure 5.5, both water soluble 
molecules take over 7 days to achieve maximum release at pH 7.4; however, in the low pH 
environment of the lysosome, maximum release should occur in only a few hours (204). While the 
burst release of R-848 and cGAMP is not ideal, these are both water soluble molecules that may 
be diffusing rapidly through the formulation to reach the external aqueous suspension. This type 
of release is not uncommon with water soluble molecules encapsulated within hydrophobic 
microparticle formulations (218) and is relatively unavoidable unless the molecular structures can 
be modified to become more hydrophobic. 
The use of PLGA as a potent adjuvant delivery vehicle would be advantageous as it is used 
in approximately 15 FDA approved drug delivery formulations (32), and therefore the path to 
clinical application would be easier to traverse. In previous work, cGAMP MPs formulated with 
PLGA showed to be less efficacious than cGAMP MPs formulated with Ace-DEX (204). It was 
theorized that the slow degradation kinetics of PLGA and minimal pH sensitivity prohibited 
cGAMP from releasing fast enough within the lysosome to induce potent cytokine production. As 
presented in Figure 5.7, Combo MPs formulated with PLGA do not illicit the robust IFN-β, IL-1β, 
or TNF response seen with Combo MPs formulated with Ace-DEX. This mirrors what was 
observed in previous work; however, the production of IL-12p70 was larger with Combo MPs 
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formulated with PLGA, which may indicate slow release kinetics for R-848 and cGAMP are 
advantageous for this particular cytokine.  
Using the model antigen Ova, mice were vaccinated with various formulations to see if the 
Combo MPs formulated with Ace-DEX could outperform all other groups like it had in vitro. 
Following the first boost, Combo MPs formulated with Ace-DEX led to the largest humoral 
response with the highest Ova specific antibody titers, even greater than Alum which is used in 
over 80% of adjuvanted vaccines (219). Blank MPs formulated with Ace-DEX led to much higher 
IgG production than Blank MPs formulated with PLGA indicating that Ace-DEX is a more ideal 
drug delivery vehicle for antigen delivery as neither formulation had high levels of endotoxin 
contamination. The R-848 MPs induced a small improvement over Blank MPs formulated with 
Ace-DEX, meaning the dose (18 ng) was too low to elicit a robust immune response by itself. This 
would imply that the antibody titers produced from the Combo MPs is not simply an additive effect 
between the two adjuvants, but rather a synergistic effect (220). Additionally, the combination of 
singularly encapsulated particles resulted in only a marginal increase in antibody titers with respect 
to cGAMP MPs, further cementing the importance of having multiple adjuvants within the same 
particle for humoral responses, which agrees with the results determined by Kasturi et al. (199). 
While total IgG generation reveals the humoral response to vaccination, IgG1 and IgG2c 
subtypes are indicative of Th2 and Th1 skewed responses, respectively (221). For certain 
pathogens, it is important to achieve a more balanced immune response because both Th1 and Th2 
responses are critical for successful clearance. The IgG subtype production for Alum are skewed 
towards a Th2 response with only production of IgG1, which is not ideal for a broad acting vaccine. 
The IgG1 responses in groups with combination adjuvant systems (Combo and singularly 
encapsulated combination), were larger than the responses seen with cGAMP alone demonstrating 
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that Th2 responses can be influenced by dual activation of the immune system. Combo MPs 
formulated with Ace-DEX were superior to all other formulations for production of IgG1, 
indicating that Th2 skewing could benefit from co-encapsulation and Ace-DEX degradation 
kinetics.  
Th1 skewing is noted to indicate long lasting immunity which is pivotal for a vaccines 
success (222). IgG2c production seemed to be independent of co-encapsulation as the Combo MPs 
formulated with Ace-DEX and the combination of singularly encapsulated cGAMP and R-848 
MPs were very similar. Additionally, Combo MPs formulated with PLGA appear to have an 
advantage over cGAMP MPs alone indicating the combination of adjuvants may override the poor 
release kinetics for Th1 skewing responses. These results shed some light on how adjuvant systems 
can improve humoral responses and indicate balanced immune skewing, which is critical for broad 
acting vaccines. However, Th1 and Th2 skewing via IgG subtypes are not indicative of cellular 
and humoral recognition of antigens and thus, CD8+ and CD4+ Tcell activity was analyzed.     
It was illustrated that the combination of singularly encapsulated particles outperformed 
the cGAMP MPs and thus, needed only to be compared to the Combo MPs formulated with Ace-
DEX for Tcell activity. IFN-γ production was measured following SIINFEKL stimulation of whole 
splenocytes, indicating that the CD8+ epitope was successfully processed. The combination of 
singularly encapsulated cGAMP and R-848 MPs, and the Combo MPs formulated with Ace-DEX 
performed well and were nearly identical in IFN-γ production. While the Combo MPs formulated 
with PLGA also showed a CD8+ response, it was smaller than that of the Ace-DEX formulations. 
These differential responses indicate that perhaps the CD8+ activity of the vaccine is not dependent 
upon co-encapsulation of adjuvants, but rather on the fast delivery of adjuvants within APCs, 
which agrees with previous work (223). IFN-γ production was measured following whole Ova 
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stimulation of splenocytes, indicating the CD4+ epitope was successfully recognized. Combo MPs 
formulated with Ace-DEX showed larger IFN-γ production than the combination of singularly 
encapsulated cGAMP and R-848 MPs and generated larger responses than Combo MPs formulated 
with PLGA. These data indicate that co-encapsulation of adjuvants and degradation kinetics of the 
vehicle can enhance CD4+ Tcell activation similar to results documented by Savelkoul et al. (224).  
Taken together, Combo MPs formulated with Ace-DEX stand as a novel and efficacious 
formulation that is superior to the cGAMP MP formulation that successfully protected mice from 
a lethal infection of influenza (204). Novel and potent adjuvant systems are in dire need to develop 
balanced immune responses to generate efficacious and safe balanced vaccines. While the AS04 
formulation system provides a balanced immune response, Combo MPs formulated with Ace-DEX 
offer a unique delivery vehicle that can passively target APCs, and deliver adjuvants extremely 
fast once internalized. The doses used within these experiments were on the nanogram scale, but 
it is possible that the formulation could still be efficacious by reducing these doses by an order of 
magnitude. Combo MPs formulated with Ace-DEX represent a highly encapsulated, potent 
adjuvant system that can be administered at extremely low doses with strong immune responses 
for vaccine applications.  
5.5 Conclusions  
Within this chapter, the production of a scalable, efficiently loaded, highly flexible 
formulation system for the generation of combinational adjuvant vaccine particles was described. 
Combo MPs formulated with Ace-DEX were shown to be superior to a combination of singularly 
encapsulated cGAMP and R-848 MPs, and Combo MPs formulated with PLGA both in vitro and 
in vivo. Robust humoral and cellular responses to Ova were shown to be predicated on degradation 
kinetics and co-encapsulation of adjuvants further cementing the importance of utilizing multiple 
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adjuvants within a single formulation for vaccines. Additionally, Ace-DEX demonstrated it was 
superior to PLGA when delivering adjuvants to APCs, and while it is not currently in clinical use, 
there is a clear niche for Ace-DEX within the vaccine formulation field.  
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Figure 5.1 cGAMP MPs Synergize with other Adjuvants to Induce Robust Cytokine 
Responses 
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Bone marrow derived dendritic cells (BMDCs) from C57BL/6 mice were harvested, and used on 
culture day 9. Cells were deprived of growth factors overnight, then left untreated (Blank) or 
treated with soluble Murabutide (10 ug/ml), MPL (1 ug/mL), Poly (dA:dT) (10 ug/mL), CpG (1 
ug/mL), Poly (I:C) (10 ug/mL) or R848 (0.01 ug/mL) alone or in combination with acetalated 
dextran microparticles encapsulating 1 µg cGAMP (cGAMP MPs), or an equivalent amount of 
Blank MPs. Cell supernatants were collected 22 hours later and were analyzed for TNF, IL-6, IL-
1β, IL-12p70 and IFN-β. Data is presented as mean ± standard deviation (n=4), *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001. 
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Table 5.1 Emulsion based Encapsulation Efficiencies of cGAMP and Resiquimod (R-848)  
Encapsulation efficiency of cGAMP, resiquimod (R-848), or a combination of both within 
acetalated dextran (Ace-DEX) or poly lactic co glycolic acid (PLGA) microparticles. 
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Figure 5.2 Multiple Fluorophore Microparticle Analysis via Flow Cytometry 
BODIPY 493/503 (FITC channel), Texas Red (Texas Red channel) and BODIPY 630/650 (APC 
channel) were loaded into acetalated dextran microparticles via co-axial electrohydrodynamic 
spraying and analyzed using flow cytometry. 
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Table 5.2 Electrohydrodynamic spray (electrospray) Encapsulation Efficiencies of cGAMP 
and Resiquimod (R-848)  
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Figure 5.3 Electrohydrodynamic spray Morphology and Release Kinetics for cGAMP and 
Resiquimod (R-848) Microparticles  
Scanning electron micrographs of A) cGAMP MPs and B) R-848 MPs were taken. Scale bar 
indicates 4µm. C) Release profiles of individually encapsulated cGAMP and resiquimod (R-848) 
MPs formulated with Ace-DEX were conducted at pH 7.4. Data is presented as mean ± standard 
deviation (n = 3). 
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Figure 5.4 In Vitro Optimal Ratio Determination for cGAMP and Resiquimod (R-848) 
Microparticles  
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Bone marrow derived dendritic cells from C57BL/6 mice were treated with indicated 
concentrations of resiquimod (R-848) and cGAMP, both of which were individually encapsulated 
within acetalated dextran (Ace-DEX) microparticles. 22 hours later supernatants were harvested 
and analyzed for IL-6, TNF, IL-1β, IL-12p70, and IFN-β. Data is presented as mean ± standard 
deviation (n = 4). 
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Figure 5.5 Morphology and Release Kinetics of Combination Microparticles  
A) Scanning electron micrographs of acetalated dextran microparticles encapsulating a 
combination of cGAMP and resiquimod (R-848) (Combo MPs). Scale bar indicates 4µm. B) 
Release profiles of cGAMP and R-848 within Combo MPs conducted at pH 7.4. Data is presented 
as mean ± standard deviation (n = 3).  
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Table 5.3 Electrohydrodynamic spray (electrospray) Encapsulation Efficiencies of 
Combination Microparticles  
Encapsulation efficiency and drug loading of acetalated dextran microparticles encapsulating a 
combination of cGAMP and resiquimod (R-848) (Combo MPs). 
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Figure 5.6 In Vitro Comparison of Co-encapsulated Microparticles and Singularly 
Encapsulated Microparticles  
Bone marrow derived dendritic cells from C57BL/6 mice were treated with indicated 
concentrations of resiquimod (R-848) and cGAMP which were delivered as soluble drug, 
singularly encapsulated acetalated dextran microparticles (cGAMP MPs + R-848 MPs), or co-
encapsulated within the same acetalated dextran microparticle (Combo MPs). 22 hours later 
supernatants were harvested and analyzed for IL-6, TNF, IL-1β, IL-12p70, and IFN-β. Data is 
presented as mean ± standard deviation (n = 4). 
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Figure 5.7 In Vitro Comparison of Combination Microparticles Formulated with Acetalated 
Dextran or Poly lactic-co-glycolic acid  
Bone marrow derived dendritic cells from C57BL/6 mice were treated with indicated 
concentrations of resiquimod (R-848) and cGAMP co-encapsulated within acetalated dextran 
(Ace-DEX) or poly lactic co glycolic acid (PLGA) microparticles. 22 hours later supernatants were 
harvested and analyzed for IL-6, TNF, IL-1β, IL-12p70, and IFN-β. Data is presented as 
mean ± standard deviation (n = 4). 
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Figure 5.8 In Vivo Humoral Responses Following Vaccination with Microparticle (MP) 
Formulations 
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C57BL/6 females were immunized intramuscularly on day 0 with PBS or OVA (10 µg) alone or 
in combination with the indicated formulations. Particles consisted of Blank MPs, R-848 MPs (18 
ng), cGAMP MPs (200 ng), a combination of cGAMP and R-848 MPs and co-encapsulated 
cGAMP and R-848 MPs (Combo MPs) formulated with acetalated dextran (Ace-DEX), or Blank 
MPs and Combo MPs formulated with poly lactic-co-glycolic acid (PLGA). Alum was used as a 
positive control. Mice received a boost with the same formulation 21 days later. One week 
following the last boost serum was collected and analyzed for A) Ova specific total IgG, B) relative 
amount of total IgG compared to cGAMP MPs, C) IgG1 and D) IgG2c. Data is presented as 
mean ± standard deviation (n = 5). 
 
 
  
126 
 
 
Figure 5. 9 CD8+ and CD4+ Tcell Responses Following in Vivo Vaccination 
C57BL/6 females were immunized intramuscularly on day 0 with PBS or OVA (10 µg) alone or 
in combination with the indicated formulations. Particles consisted of Blank MPs, a combination 
of cGAMP (200 ng) and R-848 (18 ng) MPs and co-encapsulated cGAMP and R-848 MPs (Combo 
MPs) formulated with acetalated dextran (Ace-DEX), or Blank MPs and Combo MPs formulated 
with poly lactic-co-glycolic acid (PLGA). Alum was used as a positive control. Animals received 
a boost with the same formulation 21 and 35 days later. One week following the last boost mice 
were sacrificed and whole splenocytes were stimulated with A) SIINFEKL peptide to determine 
CD8+ activity with an ELISPOT and B) whole Ova protein to determine CD4+ activity with an 
ELISA for 48 hours. Data is presented as mean ± standard deviation (n = 5). 
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Chapter 6: Summary, Conclusions and Future Directions 
6.1 Summary 
Current treatments for pathogenic infections commonly consist of high doses of pathogen-
mediated therapeutics (often in combination) to induce clearance of the infection. The use and 
misuse of pathogen-mediated therapeutics has resulted in a rise in drug-resistant and multi-drug 
resistant pathogens (225). These multiple resistant strains pose an enormous health risk because of 
their ability to survive and proliferate in the presence of strong anti-infective compounds. Anti-
infective “cocktails” are administered to combat multiple resistant strains, but they can result in 
high medical bills, extreme patient discomfort, and damage to vital organs (226). Annual estimates 
point to roughly 25,000 American deaths (227) and roughly 700,000 deaths worldwide from drug-
resistant infections (228). While these numbers are not quite as shocking as the total mortalities 
caused from all infectious diseases, these numbers will continue to rise as fewer antibiotics have 
been approved in recent years and the total number of effective antibiotics continues to drop (8). 
In fact, a woman in Nevada died in September of 2016 from a Klebsiella pneumoniae infection in 
which the bacteria was resistant to 26 different antibiotics. Due to the incredible multi drug-
resistant nature of this bacteria, it has been named the “superbug” and with no viable treatment 
options available, it will become more prevalent within hospital systems worldwide. It is 
imperative that new therapies, which can combat infectious diseases with reduced risk of resistant 
based complications, be developed.  
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This thesis is centered around the use of biodegradable vehicles for the delivery of 
therapeutics in treatment of infectious diseases, with an emphasis on alternatives to pathogen-
mediated therapeutics. Each drug delivery vehicle was selected and formulated because of its 
unique strengths to assist in delivery of its cognate therapeutic. Emulsion based acetalated dextran 
(Ace-DEX) microparticles (MPs) were formulated to deliver AR-12 for the treatment of 
intracellular pathogens because the size of the MPs would passively target infected macrophages, 
and the particles would degrade rapidly upon introduction to the lysosome. Remote loaded 
liposomes were formulated to deliver resiquimod (R-848) for the treatment of visceral 
leishmaniasis because intravenous administration of liposomes allows for accumulation in tissues 
which the parasite reside, and remote loading can allow for high encapsulation efficiencies of drug. 
Electrospun saquinavir Ace-DEX scaffolds were milled to generate microconfetti for long-acting 
delivery of saquinavir for the treatment of human immunodeficiency virus (HIV) because 
electrospinning allows for high encapsulation efficiencies of drug, and long-acting injectables 
allow for higher adherence rates. Electrohydrodynamic sprayed (electrospray) Ace-DEX MPs 
were formulated to deliver cGAMP and R-848 within the same particle for enhanced vaccine 
efficacy because enhanced delivery to dendritic cells allows for greater antigen presentation, and 
the co-axial electrospray system allow for fixed ratios of therapeutics. Each drug delivery option 
was selected to improve upon either the soluble therapeutic, or a past formulation that was shown 
to be efficacious; however, future work needs to be performed to further optimize these 
formulation platforms.  
6.2 Host-mediated Therapeutic Treatment with Sonicated Ace-DEX MPs 
  Through the experiments performed within Chapter 2, it was determined that AR-12/MPs 
generated with ethyl acetate were a more stable formulation, with better controlled release than the 
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previously formulated dichloromethane particles. Additionally, Ace-DEX particles administered 
through the intranasal route were found to have far better particle trafficking than intravenous or 
intraperitoneal administration. Finally, Ace-DEX vehicles were determined to have sterilization 
capabilities without losing efficacy of the encapsulated small molecule drug within.  
AR-12 is a host-mediated therapeutic that increases the host immune response to infections 
through upregulation of autophagy. While autophagy is an important mechanism to re-traffic 
pathogens into lysosomes for killing, it does not generate high levels of pro-inflammatory 
cytokines that would greatly benefit neighboring cells. One potential avenue to explore, is to 
generate more efficacious hydrophobic analogs of AR-12 that will allow for exceptional controlled 
release and increased activity with respect to AR-12. Finding analogs that can generate robust 
levels of pro-inflammatory cytokines leading to increased cellular communication can lead to new, 
more potent host-mediated formulations that can be used to clear infections with enhanced 
efficacy.   
6.3 Host-mediated Therapeutic Treatment with Liposomal R-848  
Through the experiments performed in Chapter 3, it was discovered that remote loaded R-
848 liposomes could drastically increase the encapsulated R-848 within liposomes as compared to 
the passively loaded formulation (229). Additionally, it was determined that remote loading of R-
848 allowed for high retention of R-848 within liposomes, which is important due to inherent 
toxicity complications. Lastly, a scale up, continuous manufacturing process was generated to 
create liposomes in a single step through liposomal electrospray that could remote load R-848 and 
produce nitric oxide at similar efficiencies as the thin-film hydration based liposomes.  
While R-848 remains a viable option as a host-mediated therapeutic, the lipid composition 
that was selected was not one mirroring clinically approved formulations such as Myocet®, 
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Doxil®, or Ambisome®. One advantage to switching to the Doxil® or Ambisome® formulation 
would be the substitution of L-α-phosphatidylcholine from chicken egg with hydrogenated (soy)L-
a-phosphatidylcholine within the liposome because of the increase in the glass transition 
temperature (Tg). By increasing the Tg of the formulation, a higher temperature could be used 
during the remote loading step, allowing for higher solubility of R-848 in the aqueous phase, and 
in turn leading to even higher encapsulation efficiencies within liposomes. Additionally, future 
work should be performed to better understand the formulation process of liposomal electrospray, 
such as determining the uni-lamellarity of the vesicles, if different solvent systems can be used to 
generate similar formulations, and if electrosprayed liposomes lead to better storage than thin-film 
hydration liposomes in similar conditions.        
6.4 Ace-DEX Microconfetti for Long-acting Treatment 
Through the experiments performed in Chapter 4, it was determined that Ace-DEX, not 
poly lactic-co-glycolic acid (PLGA) or polycaprolactone (PCL), can be used to generate 
microconfetti (MC) through formulating a scaffold and then milling it (230). Additionally, MC 
could be loaded with high efficiency and formulated with Ace-DEX of different degradation 
kinetics, allowing for differential release rates. Lastly, a single injection in vivo with fast degrading 
polymer allowed for just over a week of SQV release, and allowed for enhanced serum and tissue 
accumulation.  
While SQV reformulated into a long-acting injectable could be more preferential than the 
twice daily oral formulation, the ideal injectable would release for longer than a single week. The 
loading of Ace-DEX MC was exceptional due to the electrospinning formulation technique; 
however, longer release period’s means higher polymer loads, which can be problematic in humans 
as injection volumes are more stringent. Additionally, while Ace-DEX can be used to tunibly 
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deliver therapeutics over longer periods than shown in vivo within Chapter 4, the SQV levels in 
serum and tissue would drop as less drug would be released in a given time period. In order to 
overcome these boundaries, future MC formulations could include bolus injections of drug while 
MC is releasing to boost therapeutic levels so that high concentrations can be maintained in serum. 
Furthermore, multiple MC formulations could be injected to allow for synergistic effects or the 
inhibition of metabolic enzymes to further increase pharmacokinetic (PK) properties of drugs.  
6.5 Co-axial Electrospray of cGAMP and R-848 MPs for Vaccine Applications 
The experiments performed in Chapter 5 were to improve upon a formulation in which the 
water soluble cyclic-di-nucleotide, cGAMP, was encapsulated within Ace-DEX MPs and used in 
vaccine applications. Combining multiple adjuvants for vaccinations has previously shown to 
enhance the longevity and strength of the vaccination and thus, a multiple adjuvant therapy with 
cGAMP was investigated. The combination of cGAMP and R-848 in the same particle via co-axial 
electrospray (Combo MPs), resulted in increased cytokine responses in vitro, and increased 
antibody responses in vivo with respect to cGAMP MPs alone showing that multiple adjuvants 
can enhance a formulations efficacy. Additionally, Combo MPs formulated with Ace-DEX were 
superior to Combo MPs formulated with PLGA, highlighting the strength of Ace-DEX as an 
adjuvant carrier.  
One of the complications when delivering adjuvants is to ensure that release kinetics are 
highly controlled, as adjuvants typically have high levels of toxicity when given systemically. 
Formulating particles through co-axial electrospray allows for high encapsulation efficiencies of 
water soluble molecules that cannot typically be formulated through emulsion based procedures; 
however, this does not ensure that the release kinetics of the water-soluble molecules will be 
favorable. One way to improve release kinetics is by modifying the water-soluble molecules to 
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become more hydrophobic, which would increase the controlled release of the formulation. 
Another technique is to electrospray an emulsion or suspension rather than a co-axial electrospray 
because the water phase is likely to be repelled by the immiscible organic solvent and localize near 
the surface, making diffusion and release far less controlled.  
The formulations presented within this thesis are novel platforms for the generation of 
therapeutic options that are imperative given the complications facing treatment of infectious 
diseases. By increasing efficacy, decreasing toxicity, enhancing delivery, and modulating the PK 
of therapeutics, the drug delivery vehicles that have been described are ideal delivery systems for 
battling numerous infections.      
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